IngentaConnect Table Of Contents: European Neuropsychopharmacology

Opioids and the dynamics of addiction
pp. 77-78(2)
Author: Van Ree J.M.

Driving forces in brain research
pp. 78-79(2)
Author: Mohler H.

Can we identify an early target population in high risk studies?
pp. 81-81(1)
Authors: Johnstone E.C.; Owens D.G.C.

Prodromal psychotic states and their treatment
pp. 81-82(2)
Author: Hummer M.

Do biological findings help to identify a risk group?
pp. 82-82(1)
Author: Kahn R.S.

Atypical neuroleptics in prevention of relapse in schizophrenia
pp. 82-82(1)
Authors: Naber D.; Andersohn F.

What provokes the onset of psychosis?
pp. 83-83(1)
Author: Murray R.

Patients in depression trials
pp. 84-84(1)
Author: Montgomery S.A.

Criteria for efficacy of clinical trials in depression
pp. 84-85(2)
Author: Hackett D.

The nicotinic receptors in the human brain
pp. 85-86(2)
Author: Nordberg A.

Effects of nicotine on the mesolimbic dopaminergic reward system in brain
pp. 86-86(1)
Author: Svensson T.H.

Clinical symptomatology of nicotine withdrawal, and its control, in humans
pp. 86-87(2)
Author: Sachs D.P.L.

Chronic nicotine treatment and nicotinic receptor function
pp. 87-88(2)
Authors: Wonnacott S.; Mogg A.

Nicotine withdrawal and antidepressants: Monoaminergic and glutamatergic modulation of reward
pp. 88-89(2)
Authors: Markou A.; Kenny P.J.

Presence of dopamine D1 receptors in rat paraventricular nucleus of hypothalamus and their putative role in regulation of endocrine system - Anatomical and functional evidences
pp. 89-90(2)
Authors: Chocyk A.; Czyrak A.; Mackowiak M.; Fijal K.; Wedzony K.

BAG-1 as a candidate for causing corticosteroid receptor resistance: A functional domain analysis
pp. 90-90(1)
Authors: Schmidt U.; Rosenhagen M.; Abel A.; Holsboer F.; Rein T.

The role of the endogenous hippocampal opioid system in spatial learning
pp. 90-90(1)
Authors: Sandin J.; Ogren S.O.; Terenius L.

A stressful event dissociates food stimulating systems in hypothalamic neurons; implications for obesity and anorexia nervosa
pp. 90-91(2)
Authors: Kas M.; Bruijnzeel A.; Haanstra J.; Lubbers M.; Wiegant V.; Adan R.

Anti-amyloidogenic effect of tetracyclines in Prion and Alzheimer disease models
pp. 91-91(1)
Authors: Colombo L.; Angeretti N.; Rossi G.; Iussich S.; Colovic M.; Giaccone G.; Bugiani O.; Salmona M.; Tagliavini F.; Forloni G.

Modulation of the activity of layer V pyramidal neurons in medial prefrontal cortex by 5-HT_2A receptors. Potential role in antipsychotic drug action
pp. 91-92(2)
Authors: Puig M.V.; Celada P.; Artigas F.

Correction of dizocilpine-induced behavioral and biochemical abnormalities by dopamine D₃ receptor blockade or invalidation in the mouse
pp. 92-92(1)
Authors: Leriche L.; Diaz J.; Schwartz J.-C.; Sokoloff P.

Pharmacogenetic studies of tricyclic antidepressant response and an association study of a noradrenaline transporter variant in depression
pp. 92-93(2)
Authors: Aitchison K.J.; Tandon K.; Ashworth A.; Kerwin R.; McGuffin P.

Lithium and the treatment of mania
pp. 93-93(1)
Author: Bourgeois M.L.

Typical and atypical antipsychotics in the treatment of mania
pp. 94-94(1)
Author: Goodwin G.

Recent maintenance research in bipolar I disorder
pp. 94-95(2)
Authors: Calabrese J.R.; Bowden C.L.; Goodwin G.; Kasper S.; Yatham L.

Treatment of rapid cycling bipolar disorder
pp. 95-96(2)
Authors: Bowden C.L.; Calabrese J.R.; Thompson P.M.

Brain imaging studies on the mechanism of action of mood stabilisers
pp. 96-96(1)
Author: Soares J.C.

Gamma-secretase as a molecular target: Design, characterization and properties of new non peptidic inhibitors
pp. 96-97(2)
Authors: Checler F.; Petit A.

Can we predict the development of Alzheimer's disease through mild cognitive impairment?
pp. 97-98(2)
Authors: Soininen H.; Hanninen T.

A-immunization reduces learning impairment and amyloid plaque burden in an animal model of Alzheimer's disease
pp. 98-98(1)
Authors: Westaway D.; Janus C.; Johnson H.; Chishti M.A.; McLaurin J.; Mathews P.; Jiang Y.; Schmidt S.D.; Horne P.; French J.; Nixon R.A.; Mercken M.; Fraser P.E.; Bergeron C.; Carlson G.A.; George-Hyslop P.S.

The inflammatory hypothesis of Alzheimer's disease: Where do we stand?
pp. 98-99(2)
Author: Eikelenboom P.

Vascular problems in Alzheimer's disease
pp. 99-100(2)
Authors: Van Broeckhoven C.; Kumar-Singh S.

Control of neurosteroid biosynthesis by neurotransmitters and neuropeptides
pp. 100-101(2)
Authors: Do-Rego J.L.; Beaujean D.; Galas L.; Tonon M.C.; Luu-The V.; Fredriksson R.; Larhammar D.; Fournier A.; Pelletier G.; Vaudry H.

Neurosteroids: Functional aspects
pp. 101-102(2)
Authors: Le Moal M.; Vallee M.; Mayo W.

Neuroprogesterone: Nerve/myelin protection and repair, memory, anxiety, neuroplasticity, aging ...
pp. 102-103(2)
Author: Baulieu E.-E.

Perspective on NO in brain function
pp. 103-103(1)
Author: Garthwaite J.

NOS as targets for therapeutic strategies in brain disorders
pp. 103-104(2)
Authors: Meini A.; Benocci A.; Frosini M.; Sgaragli G.; Pessina G.; Aldinucci C.; Palmi M.

In vivo studies of glutamatergic receptors and NO pathways in brain
pp. 104-105(2)
Authors: Fedele E.; Pepicelli O.; Raiteri M.

Stress and brain nitric oxide
pp. 105-106(2)
Author: Leza J.C.

NMDA receptors and NO signalling in cerebellar synaptic plasticity
pp. 106-107(2)
Authors: Casado M.; Ascher P.

Different efficacy of antidepressants in inpatients with depression
pp. 107-107(1)
Authors: Nolen W.A.; Bruijn J.A.

Resistant depression: Patterns of treatment response
pp. 108-108(1)
Authors: Mendlewicz J.; Souery D.

Safety and efficacy of antidepressants in older people
pp. 108-109(2)
Authors: Katona C.; Livingston G.

Depression and anhedonia in Parkinson's disease
pp. 109-109(1)
Authors: Lemke M.R.; Brecht M.; Koester J.; Kraus P.H.; Reichmann H.

Cognitive deterioration in Parkinson's disease
pp. 109-110(2)
Authors: Cools R.; Robbins T.W.

Brain stimulation and the modulation of emotions in Parkinson's disease
pp. 110-111(2)
Author: Mallet L.

Brain structure changes across the lifespan of schizophrenia: Excessive gray matter changes in schizophrenia
pp. 111-112(2)
Authors: Hulshoff Pol H.E.; Cahn W.; Kahn R.S.

Animal models on schizophrenia as a neurodevelopmental disorder
pp. 112-113(2)
Authors: Gerrits M.A.F.M.; Wolterink G.; Daenen E.W.P.M.; Van Ree J.M.

Endogenous sensitization in the pathophysiology of schizophrenia: Evidence from imaging studies
pp. 114-114(1)
Author: Laruelle M.

Sensitization in the pathogenesis and natural history of schizophrenia
pp. 114-114(1)
Authors: Lieberman J.A.; Eure T.; Eure A.

Brain-derived neurotrophic factor, dopamine receptors and behavioral sensitization
pp. 114-114(1)
Author: Schwartz J.-C.

The orphan GPCRs: Targets of the future neuropsychopharmacological drugs
pp. 115-115(1)
Authors: Civelli O.; Reinscheid R.; Wang Z.; Saito Y.; Lin S.; Clark S.; Nagasaki H.; Takahashi T.; Nothacker H.P.

Control of neurotransmitter release by metabotropic glutamate receptors
pp. 115-116(2)
Author: Schoepp D.

Anatomy, physiology and pharmacology of GABA_B receptors
pp. 116-117(2)
Author: Bowery N.G.

Constitutive activity of metabotropic glutamate receptors: Role of the intracellular interacting proteins, Homer
pp. 117-117(1)
Authors: Bockaert J.; Ango F.; Prezeau L.; Worley P.F.; Pin J.-P.; Fagni L.

Inverse agonism at D2 dopamine receptors - Relevance to antipsychotic action
pp. 117-118(2)
Author: Strange P.

Low versus high doses of methadone
pp. 118-119(2)
Author: Strain E.

Evidence-based treatment with buprenorphine
pp. 119-120(2)
Author: Ling W.

Beneficial effect of heroin in heroin addicts
pp. 120-120(1)
Authors: Van den Brink W.; Hendriks V.M.; Blanken P.; Van Ree J.M.

Pharmacokinetics and pharmacodynamics of inhaled heroin: Relevance for treatment
pp. 120-121(2)
Authors: Hendriks V.M.; Van den Brink W.; Blanken P.; Van Ree J.M.

The ideal treatment of withdrawal
pp. 121-123(3)
Authors: Nutt D.J.; Law F.

Gender and gonadal steroids: Influence on HPA activity and emotional neuroactivity
pp. 123-124(2)
Author: Ingram C.

Chronic effects of perinatal stress: Dependency on gender and the genetic predisposition
pp. 124-124(1)
Authors: Neumann I.; Kroemer S.; Wigger A.

Mood disorders and sexual dimorphism in neurotransmitter systems
pp. 124-125(2)
Author: Steiner M.

Maternal depression and child psychopathology
pp. 125-126(2)
Author: Wolke D.

Mood and the menstrual cycle: Phenomenology and novel treatments
pp. 126-127(2)
Author: Eriksson E.

Cannabinoid receptors and their ligands
pp. 127-128(2)
Author: Pertwee R.

Endogenous cannabinoids and brain development
pp. 128-128(1)
Authors: Fernandez-Ruiz J.; Hernandez M.; Gomez M.; Ramos J.A.

Behavioral pharmacology of cannabinoids in animals
pp. 129-129(1)
Author: De Vry J.

Endogenous acylethanolamides modulates pain perception in mice
pp. 130-130(1)
Authors: Calignano A.; La Rana G.; Russo R.; Piomelli D.

Cannabinoid effects on neurocognition: Implications for psychosis
pp. 130-131(2)
Authors: Jentsch J.D.; Roth R.; Taylor J.; Verrico C.

The value of transgenic and gene targeted models for experimental therapeutics of Alzheimer's disease
pp. 131-131(1)
Authors: Price D.L.; Cai H.B.; Savonenko A.; Borchelt D.R.; Wong P.C.

The neurobiology of cognitive dysfunction in schizophrenia: Insights from gene expression profiling
pp. 131-131(1)
Authors: Lewis D.A.; Mimics K.; Middleton F.A.; Levitt P.

Genetic strategies for dissecting the dopamine and related systems in ADHD and bipolar disorder
pp. 131-132(2)
Authors: Kennedy J.L.; Jain U.; Petronis A.; Muglia P.

Genomic studies identify novel targets for the long term actions of mood stabilizers
pp. 132-133(2)
Authors: Manji H.K.; Zhou R.; Moore G.J.; Gray N.; Du J.; Chen G.

Regulatory issues in severe dementia
pp. 133-134(2)
Authors: Brassart L.; Raymond A.S.

Cognition changes in placebo controlled trials in severe dementia
pp. 134-135(2)
Authors: Vellas B.; Voisin T.

Long-term treatment with memantine in advanced AD
pp. 135-135(1)
Authors: Mobius H.J.; Stoffler A.

Therapy of Alzheimer's disease reducing beta-A: Now and the future
pp. 135-135(1)
Author: Giacobini E.

Atypical antipsychotics in behavioral disturbances in Alzheimer's disease
pp. 136-136(1)
Authors: Robert P.H.; Bonhomme P.; Pringuey D.

Imaging GABAA receptor subtypes with PET
pp. 136-137(2)
Author: Lingford-Hughes A.

In-vivo measurement of 5HT synthesis capacity in the human brain, using the PET/¹¹ C-methyltryptophan method: Clinical applications
pp. 137-138(2)
Authors: Benkelfat C.; Rosa P.; Leyton M.; Young S.N.; Mzengeza S.; Diksic M.

Brain spect in drug research and development (DRD): Recent advances
pp. 138-139(2)
Author: Catafau A.M.

Augmentation strategies: 5-HT and beyond
pp. 139-139(1)
Author: Cowen P.

The place of peptide systems in major depression and anxiety
pp. 139-140(2)
Author: Holsboer F.

Neurotrophic actions of antidepressants
pp. 141-141(1)
Authors: Duman R.; Thome J.

Galanin: New opportunities for antidepressant drug development
pp. 141-142(2)
Authors: Ogren S.O.; Kehr J.; Razani H.; Yoshitake T.; Madjid N.

Development and neuropeptide systems: Lessons from the hypothalamoneurohypopysial system
pp. 142-143(2)
Author: Burbach J.P.H.

Neurotrophic factors and brain ischemia
pp. 143-143(1)
Authors: Kokaia Z.; Lindvall O.

Regulation of FGF-2 gene by nicotinic receptors and its intracellular signaling mechanism in the rat brain
pp. 144-144(1)
Authors: Fuxe K.; Belluardo N.; Olsson P.-A.; Mudo G.; Liu F.-L.; Changeux J.-P.

Preclinical and clinical overview of nemifitide, a novel antidepressant
pp. 144-145(2)
Author: Feighner J.P.

VIP, novel proteins and peptide-mediated neuronal survival
pp. 145-146(2)
Authors: Gozes I.; Furman S.; Vulih I.; Segal-Ruder Y.; Fridkin M.; Brenneman D.E.

Imaging studies on negative symptoms in schizophrenia
pp. 146-147(2)
Author: Liddle P.

Depression, anxiety, and suicide in schizophrenia
pp. 147-148(2)
Author: Altamura A.C.

Efficacy of new antipsychotics on cognitive functions in schizophrenia
pp. 148-148(1)
Author: Peuskens J.

Patterns of familial aggregation of anxiety and depressive disorders in the community
pp. 148-148(1)
Author: Lieb R.

Familial transmission of panic disorder: The role of separation anxiety disorder and cognitive factors
pp. 149-150(2)
Authors: Schneider S.; Nundel B.

The burden of anxiety and depressive disorders: The ESEMeD study
pp. 150-150(1)
Author: Alonso J.

Preliminary results of the ESEMeD/MHEDEA 2000 study
pp. 150-151(2)
Author: Lepine J.P.

The interplay of distal and proximal risk factors in the aetiology of depression and anxiety
pp. 151-151(1)
Author: Ormel J.

Neurotransmitters, genetic models and anxiety
pp. 151-152(2)
Author: Toth M.

Chronic antidepressants prevent stress- and anxiogenic drug-induced increase in cortical norepinephrine concentration
pp. 152-153(2)
Authors: Biggio G.; Seu E.; Cherchi G.; Dazzi L.

5-HT1A receptor knockout mice and anxiety: Is the GABAA-benzodiazepine receptor complex involved?
pp. 153-154(2)
Authors: Olivier B.; Groenink L.; Van der Gugten J.

Melanocortin system and eating disorders
pp. 154-155(2)
Authors: Adan R.; Kas M.; Van Dijk G.

The role of GABA-A receptors subtypes in the effects of benzodiazepines
pp. 155-156(2)
Author: McKernan R.M.

Contribution of mGluR1 and mGluR5 to addiction to psycho stimulants
pp. 156-156(1)
Authors: Conquet F.; Epping-Jordan M.; Chiamulera C.; Wang J.

Prevalence and cost of anxiety disorders in the new century
pp. 156-157(2)
Author: Wittchen H.-U.

Temperamental risk factors for anxiety disorders in high risk children
pp. 157-158(2)
Authors: Biederman J.; Hirshfeld-Becker D.; Rosenbaum J.; Faraone S.

Treatment and outcome of post-traumatic stress disorder
pp. 158-159(2)
Author: Shalev A.

The new management of GAD
pp. 159-159(1)
Author: Allgulander C.

How long to treat anxiety disorders?
pp. 159-160(2)
Author: Bandelow B.

Antisuicidal effect of lithium
pp. 160-161(2)
Author: Muller-Oerlinghausen B.

Do antidepressants reduce mortality in unipolar patients?
pp. 161-161(1)
Author: Isacsson G.

Antidepressants and mortality in depressed patients with concomitant illness
pp. 162-163(2)
Authors: Roose S.P.; Yeragani V.

Do atypical neuroleptics reduce mortality among patients with schizophrenia?
pp. 163-163(1)
Author: Isometsa E.

Chemical neuroanatomy of the prefrontal cortex
pp. 163-164(2)
Author: Sesack S.

Effects on serotonin and dopamine receptors in the mechanism of atypical antipsychotic drugs
pp. 164-165(2)
Authors: Meltzer H.Y.; Kessler R.; Li Z.; Chung Y.; Ichikawa J.

Dopamine D₃ receptors: Functional significance and novel ligands as antipsychotic agents
pp. 165-166(2)
Author: Millan M.J.

Modulation of the activity of prefrontal circuits by 5-HT2A/5-HT1A receptors
pp. 166-167(2)
Author: Artigas F.

Experimental hypoglutamatergia model for cognitive deficits of schizophrenia: Effects of classical neuroleptics, 5-HT2A receptor blocking antipsychotics, the ampakine CX516 and the dopaminergic stabiliser ACR16
pp. 167-168(2)
Author: Carlsson M.L.

Anti-depressant therapy: Identification of novel targets
pp. 168-168(1)
Author: Hutson P.

A critical appraisal of antidepressant drug development
pp. 168-169(2)
Author: Bourin M.

Peptide receptors: Anything different from targeting amine systems?
pp. 169-170(2)
Authors: Hokfelt T.; Xu Z.-Q.D.; Holmberg K.; Kehr J.; Schott P.A.; Ogren S.O.; Wang F.-H.; Yoshitaki T.; Bartfai T.; Lendahl U.; Kokaia M.; Nanobashvili A.; Kokaia Z.; Lindvall O.; Kahl U.; Yamaguchi M.

Glutamatergic mechanisms in antidepressant treatments
pp. 170-171(2)
Author: Marek G.J.

Depression at adolescence
pp. 173-173(1)
Authors: Zdanowicz N.; Coremans E.; Reynaert C.

Adolescents' depression: A trouble of internality?
pp. 173-173(1)
Authors: Zdanowicz N.; Coremans E.; Reynaert C.

An empirical typology of child and adolescent depression using the grade-of-membership (GoM) analysis
pp. 173-174(2)
Authors: Rozsa S.; Csorba J.; Vetro A.; Gadoros J.

Steroid receptor inhibition by targeting heat shock protein 90
pp. 174-174(1)
Authors: Rosenhagen M.; Schmidt U.; Jason Y.; Hartl F.-U.

Construction and validation of a depression screening questionnaire in old-old patients (>75 years)
pp. 174-174(1)
Authors: Perrin E.; Vetel J.M.; Pellerin J.; Goldberger C.; Hugonot L.

Potential predictors of depression in patients with chronic hepatitis-C during long-term treatment with interferon alpha
pp. 175-175(1)
Authors: Quiner S.; Jessner W.; Rosenauer D.; De Zwaan M.; Ferenci P.; Kasper S.

Family study of recurrent depressive disorder in the patients with schizotypal disorder
pp. 175-175(1)
Author: Piatnitski N.

Predictors of improvement: Switching from daily SSRIs to fluoxetine once-weekly
pp. 175-176(2)
Authors: Brown E.; Miner C.; Gonzales J.

Long-term safety upon switching from daily SSRIs to fluoxetine once-weekly
pp. 176-176(1)
Authors: Brown E.; Miner C.; Gonzales J.; Stroud C.

Predictors of response to luteal phase fluoxetine treatment of PMDD
pp. 176-176(1)
Authors: Cohen L.; Davis S.; O'Brien P.M.S.; Brown E.; Miner C.; Jacobson J.

Rates of post traumatic stress disorder (PTSD) in a semi-rural primary care population
pp. 176-177(2)
Authors: Rotheray A.; Lenox-Smith A.J.

TNFB polymorphism may not be associated with major depressive disorder in the Korean population
pp. 177-177(1)
Authors: Jun T.-Y.; Pae C.-U.; Lee K.-U.; Chae J.-H.; Bahk W.-M.; Kim K.-S.

A placebo-controlled, double-blind trial of ginkgo biloba for antidepressant-induced sexual dysfunction
pp. 177-177(1)
Authors: Kang B.-J.; Lee S.-J.; Kim M.-D.; Jo M.-J.

Recurrence of premenstrual dysphoric disorder (PMDD) symptoms after fluoxetine treatment discontinuation
pp. 177-178(2)
Authors: Brown E.; Pearlstein T.; Miner C.; Gonzales J.

The prevalence of general anxiety disorder in the primary care population
pp. 178-178(1)
Authors: Lenox-Smith A.J.; Brown A.

Reboxetine utilization as add-on therapy to SSRI in treatment-resistant depression
pp. 178-178(1)
Authors: Tavormina G.; Corea S.; Citron A.

Omega-3 fatty acid treatment of depressive breakthrough during unipolar maintenance
pp. 178-178(1)
Authors: Stahl Z.; Nemets B.; Belmaker R.H.

Prophylactic effects of phenytoin in bipolar illness: A controlled study
pp. 179-179(1)
Authors: Bersudsky Y.; Mishory A.; Levine J.; Winokur M.; Belmaker R.H.

Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder
pp. 179-179(1)
Authors: Winkler D.; Willeit M.; Wolf R.; Stamenkovic M.; Tauscher J.; Konstantinidis A.; Pjrek E.; Schindler S.D.; Barnas C.; Kasper S.

Pharmacological treatment pattern of mania in a natural setting: A retrospective chart review 1997-1999
pp. 179-179(1)
Authors: Letmaier M.; Schreinzer D.; Thierry N.; Wolf R.; Kasper S.

Metanalysis of olanzapine-fluoxetine use in treatment-resistant depression
pp. 180-180(1)
Authors: Dube S.; Andersen S.W.; Paul S.; Corya S.A.; Van Campen L.E.; Sanger T.M.; Welge L.; Nanos J.; Tollefson G.D.

Safety metanalysis of olanzapine-fluoxetine combination versus olanzapine
pp. 180-180(1)
Authors: Corya S.; Andersen S.W.; Paul S.; Van Campen L.E.; Sanger T.M.; Tollefson G.D.; Dube S.

Olanzapine-fluoxetine combination for psychotic major depression
pp. 180-181(2)
Authors: Dube S.; Rothschild A.; Andersen S.W.; Sanger T.M.; Clemow D.B.; Tohen M.; Tollefson G.D.

Safety metanalysis of olanzapine-fluoxetine combination versus fluoxetine
pp. 181-181(1)
Authors: Corya S.; Andersen S.W.; Paul S.; Deldar A.; Sanger T.M.; Tollefson G.D.; Dube S.

Impact of racing thoughts on depression
pp. 181-181(1)
Author: Benazzi F.

Mood reactivity and atypical depression
pp. 182-182(1)
Author: Benazzi F.

Bipolar-II disorder, early-onset ''unipolar'' depression, and atypical ''unipolar'' depression relationships
pp. 182-182(1)
Author: Benazzi F.

Long-term olanzapine-fluoxetine use in major depressive disorder: Interim data
pp. 183-183(1)
Authors: Corya S.; Andersen S.W.; Dube S.; Kelly L.S.; Sanger T.M.; Williamson D.; Nowlin Z.; Tollefson G.D.

SSRI/venlafaxine discontinuation symptoms during antidepressant switching; an interim analysis
pp. 183-183(1)
Authors: Haddad P.M.; Tint A.K.; Anderson I.M.; Tiplady B.

Effect of E-6006 citrate upon schedule-induced polydipsia (SIP)
pp. 183-184(2)
Authors: Fisas M.A.; Codony X.; Laloya M.; Farre A.J.; Guitart X.

Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain
pp. 184-184(1)
Authors: Franklin M.; Murck H.

Safety metanalysis of olanzapine-fluoxetine combination versus placebo
pp. 184-184(1)
Authors: Dube S.; Andersen S.W.; Clemow D.B.; Sanger T.M.; Tollefson G.D.

Combined treatment with paroxetine and transcranial magnetic stimulation (TMS) depresses the mitogen-induced proliferation of rats' thymocytes and splenocytes
pp. 184-184(1)
Authors: Vetulani J.; Roman A.; Nalepa I.

Paroxetine pretreatment does not affect the behavioral and biochemical effects of chronic electroconvulsive shock in rats
pp. 184-185(2)
Authors: Nalepa I.; Roman A.; Kowalska M.; Vetulani J.

Pre-clinical characterisation of Lu 35-138, a dopamine D4 receptor antagonist & serotonin reuptake inhibitor, in the resident-intruder model of antidepressant drug activity
pp. 185-185(1)
Authors: Mitchell P.J.; Hogg S.

The cost effectiveness of different classes of antidepressants used in depression in the UK
pp. 185-186(2)
Authors: Lenox-Smith A.J.; Conway P.; Knight C.

Onset of action of olanzapine-fluoxetine combination for treatment-resistant depression
pp. 186-186(1)
Authors: Dube S.; Andersen S.W.; Briggs S.D.; Van Campen L.E.; Sanger T.M.; Thase M.E.

Mirtazapine orally disintegrating tablets versus sertraline: Response and remission in a prospective onset-of-actiontrial
pp. 186-186(1)
Authors: Vester-Blokland E.; Van Oers H.

Early onset of action of mirtazapine versus other new-generation antidepressants for patients in remission
pp. 187-187(1)
Authors: Van Hensbeek I.; Van Oers H.; Schutte A.J.

Mirtazapine versus other new-generation antidepressants: Pooled analysis on the onset of action
pp. 187-187(1)
Authors: Van Oers H.; Schutte A.J.; Van Hensbeek I.

Survival analysis (Kaplan-Meier; Stassen) and pattern analysis to assess the onset of action of mirtazapine versus other new antidepressants
pp. 187-187(1)
Authors: Schutte A.J.; Van Oers H.; Van Hensbeek I.

Comparison of MMPI-2 profiles of the first degree relatives of bipolar patients and normal controls
pp. 187-188(2)
Authors: Yildirim A.S.; Kabakci E.; Ulusahin A.

Prevalence of depressive disorders in perimenopausal women attending gynaecological clinics in Poland
pp. 188-188(1)
Authors: Drozdz W.; Wojnar M.; Araszkiewicz A.; Szymanski W.; Nawacka-Pawlaczyk D.; Urbanski R.

Mental disorders in the first degree relatives of bipolar patients
pp. 188-188(1)
Authors: Yildirim A.; Ulusahin A.; Kabakci E.

Cosegregation of schizophrenia and bipolar disorder in a family
pp. 188-189(2)
Authors: Ozer S.; Ulusahin A.

Sertraline efficacy in major depression: A long-term study with plasma levels
pp. 189-189(1)
Authors: Mauri M.C.; Scalvini M.E.; Cerveri G.; Volonteri L.S.; Regispani F.; Giarelli F.; Martinelli F.; Laini V.; Fiorentini A.

Negative symptoms in major depression and schizophrenia and the relation to cognitive function
pp. 189-190(2)
Authors: Stordal K.I.; Lundervold A.J.; Lund A.

Bone mineral density in female depressive patients
pp. 190-190(1)
Authors: Turan M.T.; Esel E.; Kula M.; Demir H.; Ozsoy S.; Kartalci S.; Sofuoglu S.

Do the serotonin receptors mediate anxiogenic-like effect of antidepressants in rats?
pp. 190-191(2)
Authors: Allikmets L.; Pruus K.; Matto V.

Changes in the effects of antidepressants under the influence of agonists and antagonists of 5-HT_1A receptors in rats
pp. 191-191(1)
Authors: Pruus K.; Rudissaar R.; Matto V.; Allikmets L.

Withdrawal effects in healthy volunteers following discontinuation of NAE-086, a selective 5-HT_1A-receptor agonist. A possible model for SSRI withdrawal
pp. 191-191(1)
Authors: Widerlov E.; Jostell K.-G.; Unden F.

Serotonin and neuronal plasticity relationship: A new mechanism involved in depression?
pp. 191-192(2)
Authors: Crespi F.; Bianchi M.

Antidepressant/anxiolytic-like effect of a selective 5-HT_1B receptor antagonist, SB-224289, in rodents
pp. 192-193(2)
Authors: Arban R.; Bacchi F.; Tarter G.; Bettelini L.; Price G.W.; Gerrard P.; Middlemiss D.N.

The supersensitivity of corticotropin-releasing hormone receptor 1 provided with chronic variable stress but an acute stress had no influence on the immunoreactiviry
pp. 193-193(1)
Authors: Hishinuma T.; Kanai S.; Tanaka D.; Fujii S.; Nagashima H.; Igarashi J.; Sasuga Y.; Misono A.; Hasegawa H.; Miyamoto S.; Osada K.; Kaneko R.; Asakura M.

CREB phosphorylation involved in the sensitization of tyrosine hydroxylase of locus coeruleus after chronic variable stress of the rat
pp. 193-193(1)
Authors: Tanaka D.; Kanai S.; Hishinuma T.; Fujii S.; Nagashima H.; Igarashi J.; Sasuga Y.; Misono A.; Hasegawa H.; Miyamoto S.; Osada K.; Kaneko R.; Asakura M.

Reduction and sensitization of CRH neuron in rat hypothalamic and extrahypothalamic regions after chronic variable stress
pp. 193-193(1)
Authors: Nagashima H.; Kanai S.; Tanaka D.; Hishinuma T.; Fujii S.; Igarashi J.; Sasuga Y.; Misono A.; Hasegawa H.; Miyamoto S.; Osada K.; Kaneko R.; Asakura M.

Fluvoxamine prevents the sensitization of tyrosine hydroxylase activation induced by chronic variable stress
pp. 194-194(1)
Authors: Fujii S.; Kanai S.; Hishinuma T.; Tanaka T.; Nagashima H.; Igarashi J.; Sasuga Y.; Misono A.; Hasegawa H.; Miyamoto S.; Osada K.; Kaneko R.; Asakura M.

Evidence for two components in the mechanism of action of S20098 (agomelatine) in a chronic mild stress animal model of depression
pp. 194-194(1)
Authors: Papp M.; Gruca P.; Mocaer E.

Serotonin syndrome associated with mixed episode: A prospective evaluation
pp. 194-195(2)
Authors: Liberek C.; Ragama-Pardos E.; Gervasoni N.; Dayer A.; Bertschy G.

Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extract
pp. 195-195(1)
Authors: Cervo L.; Rozio M.; Soppo C.B.E.; Riva A.; Morazzoni P.; Caccia S.

Tolerability of single versus split daily dosing of antidepressants: A meta-analysis
pp. 195-196(2)
Authors: Yildiz A.; Sachs G.S.

Serotonin transporter gene polymorphisms of major depressive disorder and dysthymic disorder
pp. 196-196(1)
Authors: Han C.S.; Lee M.S.; Jung I.K.; Kim Y.K.

Pindolol augmentation of paroxetine: A double-blind, placebo controlled trial
pp. 196-196(1)
Authors: Geretsegger C.; Bondy B.; Aichhorn W.; Keglevic M.; Stuppaeck C.

Antidepressant withdrawal constitutes a risk for the longitudinal outcome of depression: Behavioral and neurochemical evidence
pp. 196-197(2)
Authors: Jonker L.; Harvey B.; Brand L.; Heenop M.; Stein D.J.

Preliminary results of a prospective, double-blind, placebo controlled study of metyrapone as an adjunct in the treatment of major depression
pp. 197-197(1)
Authors: Jahn H.; Schick M.; Kiefer F.; Arlt J.; Kampf P.; Wiedemann K.

Problems of recognition and treatment of sexual dysfunction among patients treated with antidepressants - A Hungarian retrospective study
pp. 197-197(1)
Authors: Osvath P.; Fekete S.; Voros V.; Tenyi T.; Vitrai J.

Premenstrual symptom changes among women with mood disorders
pp. 197-198(2)
Authors: Akdeniz F.; Karadag F.; Korkmaz S.; Yucel B.

Mirtazapine in treatment of adolescents with major depression. An open-label, multicenter pilot study
pp. 198-198(1)
Authors: Haapasalo-Pesu K.M.; Vuola T.; Lahdelma L.; Marttunen M.

Hyperforin does not inhibit brain serotonin uptake for inducing antidepressant-like activity in rats
pp. 198-199(2)
Authors: Mennini T.; Bagnati R.; Cervo L.; Gobbi M.

Increased platelet vesicular monoamine transporter density in untreated major depressed patients
pp. 199-199(1)
Authors: Rehavi M.; Zucker M.; Aviv A.; Shelef A.; Weizman A.

Switch to mania upon discontinuation of long term antidepressants in patients with mood disorders (a case report and review of literature)
pp. 199-200(2)
Authors: Ali S.; Milev R.

MAO-A gene functional polymorphism in major depressive disorder
pp. 200-200(1)
Authors: Hrdina P.; Du L.; Bakish D.; Ravindran A.

Using sleep to measure relative 5HT uptake blockade
pp. 200-200(1)
Authors: Wilson S.; Bailey J.; Rich A.; Adrover M.; Nutt D.J.

Increased activity of the renin-angiotensin-aldosterone system in patients with depression - A sleep-endocrine study
pp. 201-201(1)
Authors: Murck H.; Held K.; Steiger A.

Atypical depression spectrum disorder - Neurobiology and treatment, with focus on hypericum extract
pp. 201-201(1)
Author: Murck H.

Pharmacist coaching of antidepressant users, effects on adherence, depressive symptoms and drug attitude; a randomized controlled trial
pp. 201-202(2)
Authors: Brook O.; Van Hout H.; De Haan M.; Nieuwenhuyse H.

Onset of action of olanzapine-fluoxetine combination for bipolar depression
pp. 202-202(1)
Authors: Dube S.; Andersen S.W.; Tohen M.; Vieta E.; Briggs S.D.; Van Campen L.E.; Sanger T.M.; Thase M.E.

Risperidone added to mood stabilizers in mania; is there a difference in effect depending on mood stabilizer?
pp. 202-202(1)
Authors: Yatham L.; Binder C.; Kusumakar V.; Riccardelli R.

Treatment of depression in the ''old-old'': A randomized, double-blind, placebo-controlled trial of citalopram in patients at least 75 years of age
pp. 202-203(2)
Author: Roose S.

Differential effects of acute and repeated administration of hypericum perforatum (St. John's wort) on extracellular levels of serotonin, noradrenaline and dopamine in prefrontal cortex, striatum and hippocampus of the rat
pp. 203-203(1)
Authors: Kehr J.; Yoshitake T.; Yoshitake S.; Ogren S.O.

Bidirectional interaction between galanin and 5-HT1A receptors in the regulation of hippocampal 5-HT release
pp. 203-204(2)
Authors: Kehr J.; Yoshitake T.; Wang F.-H.; Razani H.; Madjid N.; Ogren S.O.

Escitalopram in the treatment of severe depression
pp. 204-204(1)
Authors: Gorman J.; Korotzer A.; Jin J.

Effect of antidepressant medication on responses to TRH and apomorphine tests
pp. 204-204(1)
Authors: Duval F.; Monreal J.; Mokrani M.-C.; Weiss T.; Hamel B.; Macher J.-P.

Reboxetine vs venlafaxine in the treatment of severe major depression
pp. 204-205(2)
Authors: Schwartz G.; Such P.; Schatzberg A.

Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study
pp. 205-205(1)
Authors: Rapaport M.; Wilcox C.; Heiser J.; Londborg P.; Schwartz G.

Reboxetine and sexual side effects
pp. 205-205(1)
Authors: Clayton A.; Ferguson J.; Reisner J.; Brown M.; Schwartz G.; Zajecka J.

Reboxetine-associated urinary hesitancy is ameliorated by tamsulosin
pp. 205-206(2)
Authors: Demyttenaere K.; Huygens R.; Van Buggenhout R.

The augmentation effect of pindolol on onset of action of SSRI in the treatment of depression illness
pp. 206-206(1)
Authors: Magyaros E.; Haraszti L.

Reboxetine effects on cognitive functioning in depressed patients
pp. 206-206(1)
Authors: Ferguson J.; Wesnes K.; Barker K.; Schwartz G.

Therapeutic response to reboxetine in patients with major depressive disorder
pp. 206-207(2)
Authors: Dabrowska E.; Haller T.; Bartlett C.

Inadequate treatment of depression in general hospital
pp. 207-207(1)
Author: Mikirditsian O.

Economics of high dose venlafaxine in depressed patients
pp. 207-208(2)
Authors: Harrison L.; Vanoli A.; Steen N.; Young A.

A randomized, double blind, comparison of venlafaxine ER and paroxetine in outpatients with moderate to severe major depression
pp. 208-208(1)
Authors: Casabona G.M.; Silenzi V.; Guazzelli M.

Six month compliance with fluoxetine or paroxetine treatment in depressed outpatients
pp. 208-208(1)
Authors: Demyttenaere K.; Mesters P.; Dewe W.; Boulanger B.; De Bruyckere K.; Sangeleer M.; De Nayer A.; De Weirdt L.; Janssen F.; Reynaert C.; Steemans D.; Verhaeghen E.

Escitalopram - the most selective SSRI; in vitro data and in vivo binding studies using the new selective SERT ligand 3H-MADAM
pp. 209-209(1)
Authors: Brennum L.; Larsen A.; Andersen P.; Halldin C.

Efficacy and correlates of therapeutic response to sertraline in geriatric depression with comorbid medical illness
pp. 209-209(1)
Authors: Sheikh J.; Burt T.; Doraiswamy M.; Clary C.

5-HT (1A) receptor sensitivity in major depression before and after serotonin reuptake inhibitor treatment
pp. 210-210(1)
Authors: Navines R.; Gomez E.; Goti J.; Catalan R.; Gasto C.

Randomized controlled trial of a depression management program (OPTIMIND) in primary care: Impact on compliance and dropout
pp. 210-211(2)
Authors: Vergouwen T.; Povel E.; Bakker B.; Koerselman F.; Verheij T.

5-HT2/7 receptor antagonists potentiate the effects of antidepressants: An in vivo electrophysiological study
pp. 211-211(1)
Authors: Haddjeri N.; Chouvet G.; Blier P.; Zimmer L.; Astier B.; Renaud B.; Debonnel G.

Effect of acute and short-term milnacipran administration on the levels of noradrenaline in the locus coeruleus and serotonin in the dorsal raphe nucleus
pp. 211-211(1)
Authors: Bandoh T.; Hayashi M.; Hoshi K.

Modafinil as augmentation of antidepressant therapy
pp. 211-212(2)
Authors: Kogeorgos J.; Kotrotsou M.; Polonifis N.; Vounatsi B.; Kapsopoulos A.

Discontinuation of valproate in BP maintenance: One-year follow-up
pp. 212-212(1)
Authors: Toksoy O.M.; Erten E.; Verimli A.; Oral E.T.

Ketamine does not block the electroconvulsive stimulation-induced increase in cellular proliferation within the dentate gyrus
pp. 212-213(2)
Authors: Lamont S.; Hill R.; Stanwell B.; Reid I.; Stewart C.

Latency of response and efficacy of i.v. citalopram vs citalopram per os
pp. 213-213(1)
Authors: Conte G.; Campana A.; Lucchi F.; Pegoraro M.; Vincenzi P.; Sacchetti E.

The antidepressant duloxetine reduces anxiety symptom severity
pp. 213-213(1)
Authors: Goldstein D.J.; Detke M.; Lu Y.; Demitrack M.A.

Remission rates during treatment with duloxetine in patients with major depressive disorder
pp. 214-214(1)
Authors: Lu Y.; Tran P.; Detke M.

Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine
pp. 214-214(1)
Authors: Mallinckrodt C.; Goldstein D.J.; Lu Y.; Detke M.; Wiltse C.; Demitrack M.A.

Impact of depression and mania on quality of life in bipolar compared to unipolar depression and United Kingdom population norms
pp. 214-215(2)
Authors: Lecrubier Y.; Davis K.; Harris S.

Duloxetine 60 mg QD is efficacious in the treatment of depression
pp. 215-215(1)
Authors: Detke M.; Lu Y.; Goldstein D.J.; Demitrack M.A.

Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain
pp. 215-215(1)
Authors: Iyengar S.; Bymaster F.P.; Wong D.T.; Ahmad L.; Simmons R.M.A.

Safety and tolerability of the antidepressant duloxetine
pp. 215-216(2)
Authors: Tran P.; Mallinckrodt C.; Detke M.; Goldstein D.J.; Demitrack M.A.

Catecholamines plasma levels after fluoxetine administration in depressive patients
pp. 216-216(1)
Authors: Blardi P.; De Lalla A.; Auteri A.; Iapichino S.; Di Muro A.; Dell'Erba A.; Castrogiovanni P.

Single photon emission tomography of 5-HT2A receptors in drug naive depressed patients and normal controls
pp. 216-216(1)
Authors: D'haenen H.; Van Kroonenburg M.; Vanhove C.; Baeken C.; Younis I.A.; Kubben P.; Van Laere K.; Mertens J.; Bossuyt A.

Lamotrigine delays mood episodes in recently depressed bipolar I patients
pp. 216-217(2)
Authors: Bowden C.L.; Calabrese J.R.; Baldwin D.; Behnke K.; Kasper S.; Sachs G.; Yatham L.; Ascher J.; Paska W.

Lamotrigine or lithium in the maintenance treatment of bipolar I disorder
pp. 217-217(1)
Authors: Calabrese J.R.; Bowden C.L.; Fieve R.; Goodwin G.; Young T.; Montgomery P.; Leadbetter R.

Lamotrigine and rash: Review of placebo-controlled data in bipolar disorder
pp. 217-217(1)
Authors: Calabrese J.R.; Bentley B.; Huffman R.; Leadbetter R.; Evoniuk G.

Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex
pp. 217-218(2)
Authors: Rasmussen K.; Gronier B.

Prevalence of bipolar spectrum in US adults
pp. 218-218(1)
Authors: Hirschfeld R.; Calabrese J.R.; Weissman M.; Frye M.; Keck P.E.; Wagner K.; Reed M.

Demographic and clinical characteristics of bipolar I patients enrolled in two large, placebo-controlled maintenance studies
pp. 218-218(1)
Authors: Lecrubier Y.; Nuss P.; Davis K.; Harris S.

Long-term synaptic plasticity: A novel pathophysiological model for affective disorders
pp. 218-219(2)
Author: Normann C.

Lamotrigine as adjunct to paroxetine in the treatment of depression: A double-blind trial
pp. 219-219(1)
Authors: Normann C.; Walden J.; Grunze H.

Quetiapine treatment of rapid-cycling bipolar disorder: An open prospective study
pp. 219-219(1)
Authors: Ghaemi S.N.; Goldberg J.F.; Ko J.Y.; McNally E.E.

Assessment of CYP2D6 activity in depressed patients
pp. 219-219(1)
Authors: Szewczuk-Bogusawska M.; Orzechowska-Juzwenko K.; Milejski P.; Beszej J.A.; Grzesiak M.; Kiejna A.

Early VEP abnormalities in depressed patients
pp. 219-220(2)
Authors: Normann C.; Doing C.

Antipsychotic compliance evaluation
pp. 220-220(1)
Author: White R.E.

Neuropharmacological profiles of CRA0316, a nonpeptide CRF1 antagonist
pp. 220-220(1)
Authors: Oshida Y.; Chaki S.; Kawashima N.; Kumagai T.; Okubo T.; Nakazato A.; Okuyama S.

Pharmacodynamic characteristics of serotonin transporter gene polymorphism and SSRI responsiveness
pp. 220-221(2)
Authors: Kim D.K.; Lim S.-W.; Kim H.

An open label clinical trial of reboxetine in patients with major depressive disorder
pp. 221-221(1)
Authors: Demir B.; Soykan A.; Devrimci-Ozguven H.; Gogus A.; Haller T.

Longitudinal course of pediatric-onset bipolar disorder
pp. 221-221(1)
Authors: Biederman J.; Mick E.

Changes in dopamine release, metabolism and D2 receptors after denervation of the locus coeruleus projections
pp. 222-222(1)
Authors: Harro J.; Eller M.; Haidkind R.; Kivastik T.; Terasmaa A.; Kolts I.; Rinken A.; Oreland L.

Antidepressant-like effects of zinc in mice: Possible involvement of NMDA receptors and L-arginine-nitric oxide pathway
pp. 222-222(1)
Authors: Rodrigues A.L.S.; Rosa A.O.; Lin J.; Calixto J.B.; Santos A.R.

The relationship beteen the CYP2D6 genotype and side effects during the antidepressive treatment
pp. 223-223(1)
Authors: Grzesiak M.; Beszej A.; Dobosz T.

The relationship between plasma concentration of paroxetine and CYP2D6 genotype in Japanese psychiatric patients
pp. 223-223(1)
Authors: Ueda M.; Hirokane G.; Morita S.; Yokono A.; Okawa M.; Shimoda K.

Antidepressant-like effect of melatonin in the tail suspension test in mice
pp. 224-224(1)
Authors: Mantovani M.; Bonetti K.M.; Calixto J.B.; Santos A.R.; Rodrigues A.L.S.

In vitro and in vivo effects of citalopram and its enantiomers on the serotonin uptake transporter
pp. 224-224(1)
Authors: Mork A.; Kreilgaard M.; Sanchez C.; Brennum L.; Wiborg O.

Effectiveness of adding gabapentin for the treatment of resistant unipolar recurrent major depression
pp. 225-225(1)
Authors: Catalan R.; Gabilondo A.; Grau L.; Capapey J.; Tella M.; Gasto C.

Regulation of synaptic vesicle proteins by stress and antidepressant treatment
pp. 225-225(1)
Authors: Thome J.; Rapp S.; Pesold B.; Baader M.; Hu M.; Henn F.A.

Sociodemographic variables associated with major depressive episode in patients attended in primary health care centres
pp. 225-226(2)
Authors: Fabregat V.; Saiz J.; Palao D.J.; Lopez C.; Cavero M.; Escote S.

Platelet monoamine oxidase activity of psychiatric patients: Effect of treatment with monoamine oxidase inhibitors
pp. 226-226(1)
Authors: Demir B.; Ucar G.; Sevinc I.

Serotonin syndrome associated with mixed episode: A prospective evaluation
pp. 226-226(1)
Authors: Liberek C.; Bertschy G.; Ragama-Pardos E.; Gervasoni N.; Dayer A.

A meta analsis of the core features of pediatric bipolar disorder
pp. 226-227(2)
Authors: Mick E.; Biederman J.; Faraone S.

Serotonin transporter polymorphism and long-term effect of antidepressant treatment
pp. 227-227(1)
Authors: Lee M.S.; Lee H.Y.

The impact of G-2694A and C734A polymorphism of CYP1A2 on the metabolism of clomipramine in Japanese depressive patients
pp. 227-228(2)
Authors: Hirokane G.; Ueda M.; Morita S.; Yokono A.; Okawa M.; Shimoda K.

Efficacy of venlafaxine on a derived self-rating scale of well being
pp. 228-228(1)
Authors: Bech P.; Hackett D.; Pitrosky B.

Psychotropic preparation: Influence on the immunity in clinics of mental disorders
pp. 228-229(2)
Authors: Ivanova S.; Vetlugina T.; Semke V.; Kornetov N.

Escitalopram: A comparative in vitro study of 5-HT uptake inhibition and binding in a COS-1 cell line expressing the human 5-HT transporter
pp. 229-229(1)
Authors: Wiborg O.; Sanchez C.

Effect of the 5-HT1A agonist gepirone HCL and its metabolite 3'-OH-gepirone on the 5-HT system in the rat brain
pp. 229-229(1)
Authors: Blier P.; Dong J.; Haddjeri N.

Lack of venlafaxine CYP3A4 inhibitory effects on oral and IV model substrates
pp. 229-230(2)
Authors: DeVane L.; Donova J.; Liston H.; Markowitz J.; Risch C.; Willard L.

The preclinical antidepressant-like profile of the 5-HT1A receptor agonist gepirone HCL and its metabolite, 3'-OH-gepirone
pp. 230-230(1)
Authors: Ward N.; Shahid M.; Walker G.; Westwood P.; Elands C.; Hill D.

Gepirone extended release (ER): New evidence for efficacy in the treatment of major depressive disorder (MDD)
pp. 230-230(1)
Authors: Feiger A.D.; Heiser J.F.; Shrivastava R.K.; Weiss K.J.; Smith W.T.; Sitsen J.M.A.; Gibertini M.

A double-blind placebo-controlled study of sertraline in the prevention of depression in stroke patients
pp. 231-231(1)
Authors: Rasmussen A.; Lunde M.; Sorensen K.; Qvitzau S.; Bech P.

Escitalopram offers early separation from placebo in the treatment of depression
pp. 231-231(1)

Efficacy and safety of sertraline in the treatment of pediatric major depressive disorder (MDD)
pp. 231-232(2)
Authors: Wagner K.; Donnelly C.; Wohlberg C.

Remission rates in elderly depressed patients treated with sertraline
pp. 232-232(1)
Authors: Sheikh J.; Newhouse P.; Burt T.; Clary C.

Symptom pattern analysis of premenstrual dysphoric disorder (PMDD)
pp. 232-232(1)
Authors: Pearlstein T.; Gillespie J.A.

Depression in primary care patients: Improvement during long-term escitalopram treatment
pp. 232-233(2)
Authors: Wade A.; Despiegel N.; Reines E.H.

Onset of action of NaSSA Mirtazapine: Results from an antidepressant-naive group
pp. 233-233(1)
Authors: Cobo J.; Rojo J.E.; Gibert K.; Rodriguez E.

Onset of action of Mirtazapine: A review of comparative studies
pp. 233-234(2)
Authors: Cobo J.; Rojo J.E.; Rodriguez E.; De Pedro J.M.

Sertraline vs. fluoxetine in high severity major depression: Response and remission rates from head-to-head comparator trials
pp. 234-234(1)
Authors: Flament M.; Gillespie J.A.

Comparison of the efficacy of two approaches to amitriptilyne dose individualization
pp. 234-235(2)
Authors: Mihajlovic G.; Ristic D.I.; Jankovic S.; Rikanovic M.

Depression-free days as a flexible measure of response, remission, and elimination of residual symptoms: A pooled analysis of venlafaxine, SSRIs, and placebo
pp. 235-235(1)
Authors: Mallick R.; Schatzberg A.

Quetiapine vs placebo as adjunct to mood stabilizer for the treatment of acute mania
pp. 235-236(2)
Authors: Sachs G.; Mullen J.A.; Devine N.A.; Sweitzer D.E.

Sertraline treatment of major depression in patients with acute MI or unstable angina
pp. 236-236(1)
Authors: Swenson J.R.; Van Zyl L.T.; Forman L.; Glassman A.; Barton D.; Clary C.; Harrison W.

Hormone replacement therapy for postmenopausal women on SSRIs: Preliminary results in 9 patients
pp. 236-236(1)
Author: Joe S.H.

Prophylactic treatment with venlafaxine significantly reduces depression recurrence rates even when stringent recurrence criteria are applied
pp. 237-237(1)
Authors: Keller M.B.; Kunz N.R.; Zhang J.; Wickland C.

Remission after long-term treatment with venlafaxine
pp. 237-238(2)
Authors: Keller M.B.; Entsuah R.; Kunz N.R.

Remission based on HAM-D subscales
pp. 238-238(1)
Authors: Entsuah R.; Zhang J.

Venlafaxine offers significant therapeutic benefits over existing SSRI treatments irrespective of the patient's depressive duration
pp. 238-238(1)
Authors: Entsuah R.; Kelsey J.

Olanzapine in the treatment of bipolar depression
pp. 238-239(2)
Authors: Tohen M.; Vieta E.; Kettter T.; Centorino F.; Calabrese J.; Sachs G.; Bowden C.L.; Risser R.C.; Baker R.W.; Evans A.R.; Dube S.; Tollefson G.D.; Breier A.

The new GRID-HAM-D - Results from field trials
pp. 239-239(1)
Authors: Kalali A.; Bech P.; Williams J.; Kobak K.; Lipsitz J.; Engelhardt N.; Evans K.; Olin J.; Pearson J.; Rothman M.

Topiramate as a mood stabilizer for epilepsy comorbid with mood disorders
pp. 239-239(1)
Author: Momtazi S.

IDN 5491 (Hyperforin trimethoxybenzoate): A new antidepressive drug
pp. 240-240(1)
Authors: Bombardelli E.; Morazzoni P.; Riva A.

Successful treatment of reboxetine-associated urinary hesitancy with tamsulosin
pp. 240-240(1)
Authors: Kasper S.; Wolf R.

Serotonin 5-HT1A receptors: Changes induced by long-term imipramine treatment
pp. 240-241(2)
Authors: Gomez E.; de Osaba M.J.M.; Navines R.; Catalan R.; Salamero M.; Gasto C.

The influence of hypericum extract on the hypothalamic-pituitary adrenocortical (HPA) system regulation in depressive patients
pp. 241-241(1)
Authors: Holsboer-Trachsler E.; Hatzinger M.; Hemmeter U.

Long-term course of depression: Impact of hypothalamic-pituitary-adrenocortical (HPA) system function and sleep EEG variables
pp. 241-241(1)
Authors: Hatzinger M.; Brand S.; Hemmeter U.; Baumann K.; Annen B.; Holsboer-Trachsler E.

High platelet-5HT uptake activity is associated with a rapid response in depressed patients treated with amitriptyline
pp. 242-242(1)
Authors: Franke L.; Schewe H.-J.; Uebelhack R.; Muller-Oerlinghausen B.

Influence of immunotherapy with interferon-alpha on serum amino acids, biopterin and neopterin in high risk melanoma patients
pp. 242-242(1)
Authors: Van Gool A.R.; Fekkers D.; Kruit W.H.J.; Ten Hagen T.L.M.; Bannink M.; Maes M.; Eggermont A.M.M.

Effects of nemifitide on brain NPY levels and swim test immobility in a genetic animal model of depression
pp. 242-243(2)
Authors: Overstreet D.H.; Mathe A.A.; Nicolau G.; Feighner J.P.; Jimenez-Vasquez P.A.; Hlavka J.; Morrison J.; Abajian H.

The role of arginine-vasopressin in antidepressant and memory improving effects of venlafaxine
pp. 243-243(1)
Authors: Nowakowska E.; Kus K.; Patyk M.

Parameters of spectral analysis of the variability of the heart rhythm in treating depression and seasonality
pp. 243-243(1)
Authors: Andruskevicius S.; Maciulis V.

Parameters of spectral analysis of the variability of the heart rhythm and severity of depression
pp. 244-244(1)
Authors: Andruskevicius S.; Maciulius V.

Polyunsaturated fatty acid deficit in patients with bipolar mania: A possible connection between therapeutic and psychoimmunological findings
pp. 244-244(1)
Authors: Su K.P.; Chiu C.C.; Huang S.Y.

Synergistic effect of antidepressant drugs and metyrapone, a corticosterone synthesis inhibitor, in the forced swimming test in rats
pp. 244-245(2)
Authors: Rogoz Z.; Maj J.

Effect of repeated treatment with reboxetine on the central ₁-adrenergic and dopamine system
pp. 245-245(1)
Authors: Skuza G.; Rogoz Z.; Dziedzicka-Wasylewska M.

Efficacy of psychoeducation in compliant bipolar I patients
pp. 245-246(2)
Authors: Colom F.; Vieta E.; Goikolea J.M.; Martinez-Aran A.; Reinares M.; Torrent C.; Gasto C.

Maternal treatment with antidepressants in breast-feeding mother-infant pairs
pp. 246-246(1)
Authors: Berle J.O.; Steen V.M.; Spigset O.

Lithium and the circadian rhythms of the renal sodium, potassium, calcium and lithium excretions in rats with the right suprachiasmatic nucleus lesion
pp. 246-247(2)
Authors: Zamoshchina T.; Meleshko M.; Matveenko A.; Ivanova E.; Grubel N.

Depression in college students in Bombay: A study of 2273 individuals
pp. 247-247(1)
Authors: Parikh R.; Chakraborthy N.; Sonawalla S.; Mehra G.; Dracas S.; Fava M.

Depressive disorders among minority and nonminority college students
pp. 247-247(1)
Authors: Sonawalla S.; Neault N.; Hughes M.; Petersen T.; Dording C.; Yeung A.; Fava M.

Effects of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex
pp. 247-248(2)
Authors: Nakayama K.; Wakutsu N.; Ushijima S.

The novel antidepressant, S35966, is a mixed serotonin and noradrenaline reuptake inhibitor and an antagonist at ₂-adrenoceptors
pp. 248-248(1)
Authors: Gobert A.; Cussac D.; Lejeune F.; Newman-Tancredi A.; Audinot V.; Boutin J.A.; Carr C.; Milligan G.; Rivet J.-M.; Brocco M.; Dekeyne A.; Lacoste J.-M.; Cordi A.; Millan M.J.

Combination of chronic mild stress and forced swim test in male and female rats: Behavioral and neurochemical effects
pp. 249-249(1)
Authors: Dalla C.; Xagoraris M.; Daskas S.; Antoniou K.; Sfikakis A.; Papadopoulou-Daifoti Z.

Forced swim stress in male and female rats: Behavioral and neurochemical effects
pp. 249-249(1)
Authors: Drossopoulou G.; Xagoraris M.; Dalla C.; Antoniou K.; Papadopoulou-Daifoti Z.

Influence of sertraline treatment on neurophysiological parameters in patients with obsessive-compulsive disorder
pp. 250-250(1)
Authors: Juckel G.; Mavrogiorgou P.; Goebel C.; Schenkel I.; Zaudig M.; Hegerl U.

Olanzapine as an add-on treatment for dysphoric mania in bipolar I rapid cycling patients
pp. 250-250(1)
Authors: Gonzalez-Pinto A.; Tohen M.; Lalaguna B.; Perez-Heredia J.L.; Fernandez-Corres B.; Gutierrez M.; Mico J.A.

Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomised trial
pp. 251-251(1)
Authors: Rossini D.; Franchini L.; Smeraldi E.; Zanardi R.

Venlafaxine vs fluoxetine, fluvoxamine and paroxetine: Onset of antidepressant action in patients with recurrent depression
pp. 251-252(2)
Authors: Keller M.B.; Nemeroff C.B.; Hackett D.; Haudiquet V.

Early discontinuation and long-term therapy in new SSRI users
pp. 252-252(1)
Authors: Meijer W.; Heerdink E.R.; Van Eijk J.T.M.; Leufkens H.G.M.

Rapid transcranial magnetic stimulation (r-TMS): A novel treatment option for seasonal affective disorder (SAD)?
pp. 252-252(1)
Authors: Konstantinidis A.; Heiden A.; Stastny J.; Baecker C.; Letmaier M.; Winkler D.; Neumeister A.; Kasper S.

C825T polymorphism in the G protein beta3-subunit gene is associated with seasonal affective disorder
pp. 252-253(2)
Authors: Willeit M.; Praschak-Rieder N.; Zill P.; Neumeister A.; Ackenheil M.; Kasper S.; Bondy B.

A double-blind, randomized study of the efficacy and safety of venlafaxine extended release (ER) versus fluoxetine in outpatients with major depression
pp. 253-253(1)
Author: Mehtonen O.-P.

Cellular localization of neurotransmitter receptors involved in the local control of serotonergic neurons: A double in situ hybridization study throughout the midbrain raphe nuclei
pp. 253-254(2)
Authors: Serrats J.; Mengod G.; Cortes R.

Escitalopram is efficacious and well tolerated in the treatment of depression in primary care
pp. 254-254(1)
Authors: Reines E.H.; Loft H.; Lepola U.

Escitalopram is a new and highly efficacious SSRI in the treatment of major depressive disorder
pp. 254-255(2)
Authors: Montgomery S.A.; Huusom A.K.T.; Bothmer J.

Analysis of genetic polymorphis of dopamine D3 and serotonin 5-HT2a receptor genes in the Korean schizophrenics
pp. 255-255(1)
Authors: Kim Y.W.; Hahn H.M.; Han J.Y.; Choe B.M.

Incidence of schizofrenia in Surinam: Selective immigration?
pp. 255-255(1)
Authors: Hanoeman M.; Selten J.P.; Timmerman L.; Kahn R.S.

Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study
pp. 255-256(2)
Authors: Kinon B.; Stauffer V.; Wang L.; Thi K.; Kollack-Walker S.

Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation
pp. 256-256(1)
Authors: Baker R.; Kinon B.; Liu H.; Richey A.; Hill A.; Bergstrom R.; Schuh L.

Olanzapine versus divalproex sodium for bipolar mania in rapid cyclers
pp. 256-256(1)
Authors: Baker R.; Tohen M.; Brown E.; Schuh L.; Zarate C.; Suppes T.

Plasma homocysteine in schizophrenia
pp. 256-257(2)
Authors: Ruderman V.; Stahl Z.; Sela B.-A.; Belmaker R.H.; Levine J.

Validation of a manic-like symptom scale from the positive and negative syndrome scale
pp. 257-257(1)
Authors: Brown E.; Lindenmayer J.P.; Baker R.; Shao L.; Schuh L.; Tohen M.; Stauffer V.

A factor structure of methamphetamine psychotic symptoms
pp. 257-258(2)
Authors: Srisurapanont M.; Ali R.; Marsden J.; Sunga A.; Wada K.; Monteiro M.

Effects of conventional and atypical antipsychotics on hypothalamic-pituitary-thyroid axis in patients with schizophrenia
pp. 258-258(1)
Authors: Esel E.; Sofuoglu S.; Kula M.; Turan M.T.; Izgi H.B.

Correlations between first episode of schizophrenia, neuropsychological impairment and regional cerebral blood flow
pp. 258-259(2)
Authors: Gheorghe M.-D.; Grigorescu G.; Baloescu A.

Reasons for discontinuation of clozapine
pp. 259-259(1)
Authors: Haddad P.M.; Mohan A.; Singh R.; Campbell M.; Miller J.; Majchrzakowska K.

The relationships of electrodermal responsiveness, selective attention deficits and MRI brain imaging in schizophrenics
pp. 259-260(2)
Authors: Zuardi A.; Crippa J.; Sanches R.; Hallek J.; Santos A.C.; Araulo D.; Guimares F.; Montagnat J.

A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States
pp. 260-260(1)
Authors: Cavazzoni P.; Hornbuckle K.; Hutchins D.; Jovanovic L.; Breier A.; Buse J.

Cognitive and overall functioning in institutionalised patients taking typical versus atypical antipsychotics
pp. 260-261(2)
Authors: Cervilla J.; Ana R.; Hoyos G.; Minguez L.; de Pablos E.G.

Endophenotype assessments in a large schizophrenia pedigree
pp. 261-261(1)
Authors: Ozer S.; Gonul A.S.; Ulusoy S.; Heutink P.; Claes S.; Akarsu A.N.; Ulusahin A.

Influence of long-lasting administration of neuroleptics on glutamatergic transmission in rats
pp. 261-261(1)
Authors: Pietraszek M.; Wardas J.; Golembiowska K.; Bijak M.; Wolfarth S.; Ossowska K.

Effects of classical and atypical antipsychotics on serum folic acid and vitamin B12 levels in schizophrenic patients
pp. 262-262(1)
Authors: Sofuoglu S.; Esel E.; Kula M.; Turan M.T.; Izgi H.B.; Bilgin A.

Selective dopamine/serotonin receptors mediate actions of newer antipsychotic agents
pp. 262-262(1)
Authors: Tarazi F.I.; Zhang K.; Baldessarini R.J.

Lamotrigine in clozapine-resistant schizophrenia: A randomized placebo-controlled cross-over trial
pp. 263-263(1)
Authors: Tiihonen J.; Hallikainen T.; Ryynanen O.-P.; Repo-Tiihonen E.; Kotilainen I.; Eronen M.; Toivonen P.; Wahlbeck K.; Putkonen A.

Analysis of a functional serotonin transporter gene polymorphism of normal controls and patients with schizophrenia in Korean population
pp. 263-263(1)
Authors: Paik I.H.; Lee C.; Kim J.J.; Lee S.J.; Lee C.U.; Jung K.I.

Quetiapine clinical use in real-life environment-The SECURE study
pp. 263-264(2)
Authors: Gillain B.; Van Peborgh P.; De Brueeker G.; Peuskens J.

Weight gain during psychiatric inpatient treatment
pp. 264-264(1)
Author: Rittmannsberger H.

Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia
pp. 264-265(2)
Authors: Budiman R.; Gondoyoewono H.; Chaudhry H.R.; Hashmi I.T.; Habil M.H.; Rahman A.H.B.A.; Samanwongthai U.; Levitt L.; Becker S.; Buenaventura R.

Enhanced amphetamine-induced striatal [11C]raclopride displacement by the group II metabotropic glutamate receptor agonist LY354740 in baboons
pp. 265-265(1)
Authors: Van Berckel B.N.M.; Waterhouse R.N.; Hwang D.R.; Mawlawi O.; Huang Y.; Kegeles L.S.; Van Heertum R.L.; Laruelle M.

Risperidone plus benzodiazepines as an effective and well tolerated treatment for acute psychotic patients
pp. 265-266(2)
Authors: Baciu D.; Braendle D.

CYP2D6 genetic polymorphism and extrapyramidal side effects of antipsychotic drugs
pp. 266-266(1)
Authors: Plesnicar B.K.; Dolzan V.; Zalar B.; Tomori M.; Breskvar K.

Does the intracellular signalling system associated to the serotonergic 5-HT_2A receptor activation predict clinical response to olanzapine in drug-free schizophrenic patients?
pp. 266-267(2)
Authors: Arranz B.; Ramirez N.; Duenas R.; Sarro S.; Sanchez J.M.; Cano R.; San L.

Switching to quetiapine in schizophrenic patients with antipsychotic-induced extrapyramidal symptoms
pp. 267-267(1)
Authors: Bovio H.; Jimenez J.; Herranz S.; Estiarte R.; Ovejero C.; Perez A.; Riso-Villademoros F.

Cognitive functioning and subjective well-being in schizophrenia after six month quetiapine treatment
pp. 267-268(2)
Authors: Herold R.; Simon M.; Tenyi T.; Trixler M.

AD-5423 versus haloperidol in the treatment of schizophrenic patients: Results of the Japan multicentre, double-blind trial
pp. 268-268(1)
Author: Murasaki M.

The effect of risperidone versus haloperidol on sleep patterns of schizophrenic patients - Results of a double-blind, randomised pilot trial
pp. 268-269(2)
Authors: Haffmans J.; Oolders J.M.; Hoencamp E.; Arends J.B.A.M.

Sleep quality in schizophrenic patients and the effects of antipsychotic medication
pp. 269-269(1)
Author: Schreiner A.

Lack of proarrhythmic activity for the antipsychotic drug sertindole despite a strong lkr blockade: Comparison to other antipsychotics
pp. 269-270(2)
Authors: Frederiksen K.; Adamantidis M.; Matz J.

The antipsychotic potential of the anandamide transporter inhibitor AM-404 in rodents
pp. 270-270(1)
Authors: Pouzet B.; Didriksen M.; Hertel P.

The effect of quetiapine on aggresive/hostility symptoms in patients with schizophrenia
pp. 270-270(1)
Authors: Giner J.; Gibert J.; Jimenez J.; Bovio H.; Herranz S.; Perez A.; Ovejero C.; Rico-Villademoros F.

European dose-ranging study: Sertindole is efficacious and superior to haloperidol with respect to extrapyramidal symptoms in patients with schizophrenia
pp. 271-271(1)
Authors: Hale A.; Sloth-Nielsen M.

Efficacy of quetiapine in patients with schizophrenia and suicidal behavior
pp. 271-271(1)
Authors: Vallejo J.; Giner J.; Vegazo O.; Herranz S.; Jimenez J.; Ovejero C.; Perez A.; Rico-Villademoros F.

The influence of age on plasma levels of risperidone and 9-hydroxyrisperidone
pp. 271-272(2)
Authors: Aichhorn W.; Marksteiner J.; Weiss U.; Walch T.; Kemmler G.; Zernig G.; Saria A.; Geretsegger C.

Tolerability and effectiveness of three methods of switching to quetiapine
pp. 272-272(1)
Authors: Jimenez J.; Herranz S.; Bovio H.; Vegazo O.; Rico-Villademoros F.; Ovejero C.

Functional connectivity and regional brain activity in schizophrenia
pp. 272-272(1)
Authors: Canive J.M.; LaNoue M.; Heller W.; Edgar J.C.; Miller G.A.

Schizophrenia P50 sensory gating deficit and atypical antipsychotics
pp. 273-273(1)
Authors: Canive J.M.; Thoma R.J.; Edgar J.C.; Hanlon F.; Moses S.; Bustillo J.; Huang M.; Miller G.A.

Neurocognitive functioning and subjective well-being of schizophrenic patients on quetiapine in comparison to conventional antipsychotics: A 6 months follow-up study
pp. 273-273(1)
Authors: Simon M.; Herold R.; Tenyi T.; Trixler M.

Social functioning and quality of life of patients with first episode schizophrenia
pp. 273-274(2)
Authors: Gorna K.; Suwalska A.; Jaracz K.; Rybakowski J.

Behavioral effects of acuute and chronic treatment with atypical antipsychotics in combination with ligands of serotonin receptors
pp. 274-274(1)
Authors: Rudissaar R.; Pruus K.; Allikmets L.

SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions
pp. 274-274(1)
Authors: McCreary A.C.; Glennon J.; Tuinstra T.; Herremans A.H.J.; Van der Heyden J.A.M.; Feenstra R.; Long S.K.; Kruse C.G.

Anticipation in schizophrenia: The results of multiple regression analysis
pp. 275-275(1)
Author: Zivanovic O.

Is deficit syndrome a separate disease within the syndrome of schizophrenia?
pp. 275-276(2)
Authors: Yazici K.; Tiryaki A.; Anil A.E.; Kabakci E.; Godup A.

Antipsychotics and glucose, insuline, lipids, prolactin, uric acid metabolism in schizophrenia
pp. 276-276(1)
Authors: Kurt E.; Oral E.T.

Effectiveness of risperidone in highly agitated schizophrenic patients
pp. 276-276(1)
Authors: Pajonk F.-G.; Raedler T.J.; Schreiner A.; Wiedemann K.

Risperidone in the initial treatment of acutely exacerbated schizophrenic patients
pp. 276-276(1)
Authors: Pajonk F.-G.; Schreiner A.; Peters S.; Ruther E.

Relationship between quetiapine dose and efficacy
pp. 277-277(1)
Authors: Small J.G.; Kolar M.C.; Kellams J.J.

SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology
pp. 277-277(1)
Authors: Glennon J.; McCreary A.C.; Ronken E.; Siarey R.; Hesselink M.B.; Feenstra R.; Van Vliet B.; Long S.K.; Kruse C.G.

Iloperidone is effective and well tolerated in the long term treatment of schizophrenia and schizoaffective disorder
pp. 277-278(2)
Authors: Fairweather D.B.; Young F.; Zaninelli R.

Efficacy and tolerability of iloperidone in elderly patients with psychotic and behavioural symptoms associated with dementia
pp. 278-278(1)
Authors: El-Bizri H.; Fairweather D.B.; Guven A.; Zaninelli R.

An observational study of patients with treatment-resistant schizophrenia switched to olanzapine
pp. 279-279(1)
Authors: Karagianis J.; LeDrew K.

Symptom dimensions in schizophrenia and other psychotic disorders
pp. 279-279(1)
Authors: Yazici K.; Ozdemir H.; Turgut I.T.; Rezaki M.; Gogus A.

Anticipation: One latent dimension of the schizophrenic disorder
pp. 279-280(2)
Authors: Zivanovic O.; Borisev L.

Study of ventricular repolarisation in patients treated with antipsychotics
pp. 280-281(2)
Authors: Monreal J.; Valdebenito M.; Duval F.; Tugler J.; Macher J.-P.; Roegel J.-C.

Cytosolic phospholipase A2 gene polymorphism and eye movement disturbances in schizophrenia
pp. 281-281(1)
Authors: Rybakowski J.; Borkowska A.; Czerski P.; Hauser J.

Heart rate variability in patients treated with antipsychotics
pp. 281-281(1)
Authors: Monreal J.; Duval F.; Valdebenito M.; Tugler J.; Macher J.-P.; Roegel J.-C.

Hospitalization rates decrease during long-term treatment with long-acting risperidone injection
pp. 281-282(2)
Authors: Chue P.; Devos E.; Duchesne I.; Leal A.; Mehnert A.

Long-acting, injectable risperidone - the first long-acting, atypical antipsychotic - improves quality of life
pp. 282-282(1)
Authors: Nasrallah N.; Duchesne I.; Mehnert A.; Janagap C.

Is antipsychotic-induced weight gain related to sexual dysfunction?
pp. 282-283(2)
Authors: Rejas J.; Bobes J.; Garcia-Garcia M.; Rico-Villademoros F.; Garcia-Portilla M.P.; Madrigal M.; Hernandez G.

Effects of intra-accumbal injection of dopamine D3 ligands on rat behaviour
pp. 283-283(1)
Authors: Elekes O.; Gyertyan I.

A comparison of the outcomes and costs of risperidone and olazapine treatment in The Netherlands
pp. 283-284(2)
Authors: Loonen A.J.M.; Gerdes J.H.; Van Berkestijn J.W.B.M.; Veefkind A.H.; Kaasenbrood A.J.A.; Fouwels A.J.; Hoogenboom B.; Weeda J.N.

Study on effects of typical antipsychotic, haloperidol on regional cerebral blood flow with 99mTc-HMPAO SPECT in drug-naive schizophrenic patients
pp. 284-284(1)
Authors: Kamoya M.; Koiwa D.; Jibiki I.; Kubota T.; Watanabe K.; Iwasaki S.; Higashi K.; Noda M.

Less switching after initial start with atypical antipsychotics
pp. 284-284(1)
Authors: Hugenholtz G.; Heerdink E.R.; Leufkens H.G.M.; Nolen W.A.

Schizophrenic patients' knowledge about their psychiatric diagnosis and psychiatrists' information policy
pp. 285-285(1)
Authors: De Hert M.; Wampers M.; Peuskens J.

Olanzapine treatment of the depressive symptoms in schizophrenia
pp. 285-285(1)
Authors: Chojnacka-Wojtowicz J.; Taflinski T.

The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in young and aged rats
pp. 285-286(2)
Authors: Rosengarten H.; Quartermain D.

Antipsychotic treatment of geropsychiatric inpatients
pp. 286-286(1)
Authors: Kovacs A.; Osvath P.; Trixler M.

Use of dehydroepiandrosterone in the management of negative symptoms of schizophrenia
pp. 286-286(1)
Authors: Strous R.; Maayan R.; Lapidus R.; Stryjer R.; Lustig M.; Kotler M.; Weizman A.

Extrapyramidal symptoms with atypical antipsychotics: A [123i]IBZM SPECT study
pp. 287-287(1)
Authors: De Mendelssohn A.; Kufferle B.; Asenbaum S.; Tauscher-Wisniewski S.; Kasper S.; Tauscher J.

Effect of clozapine treatment on serum leptin and insulin levels and body composition
pp. 287-288(2)
Authors: Kyvyrcyk B.B.; Alptekin K.; Calyskan S.; Comlekci A.; Oruk G.; Tumuklu M.; Kurklu K.; Arkar H.; Turk A.

Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia
pp. 288-288(1)
Authors: Carson W.; McQuade R.; Saha A.; Torbeyns A.; Stock E.

Aripiprazole for long-term maintenance treatment of schizophrenia
pp. 288-288(1)
Authors: McQuade R.; Carson W.; Saha A.; Ingenito G.; Ali M.; Archibald D.

Safety and tolerability of aripiprazole at doses higher than 30 mg
pp. 288-288(1)
Authors: Auby P.; Saha A.; Ali M.; Ingenito G.; Wilber R.; Bramer S.

Effects of single and multiple ascending doses of amisulpride in the pharmaco-EEG of healthy young male volunteers
pp. 289-289(1)
Authors: Legangneux E.; Dietrich B.; Stephan K.

Aripiprazole versus placebo in acute mania
pp. 289-289(1)
Authors: Marcus R.; Saha A.; Jody D.; Tourkodimitris S.; Archibald D.; Iwamoto T.

Comorbid panic symptoms and relation with clinical correlates in schizophrenia
pp. 289-290(2)
Authors: Alptekin K.; Ulas H.; Kyvyrcyk B.B.; Tumuklu M.; Akvardar Y.; Kitip A.

Meta-analysis of the safety and tolerability profile of aripiprazole in schizophrenia
pp. 290-290(1)
Authors: McQuade R.; Saha A.; Kaplita S.; Archibald D.; Iwamoto T.; Stock E.

Meta-analysis of weight effects with aripiprazole
pp. 290-290(1)
Authors: Jody D.; Saha A.; Iwamoto T.; Biswas D.; Lin C.-Y.; Marcus R.; McQuade R.

Aripiprazole: A dopamine-serotonin system stabilizer
pp. 290-291(2)
Authors: Byars A.; Burris K.; Jordan S.; Tottori K.; Kikuchi T.; McQuade R.

Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis
pp. 291-291(1)
Authors: Carson W.; Cornblatt B.; Saha A.; Ali M.; Kern R.; Green M.

Sequential IM/oral ziprasidone vs haloperidol in severe schizophrenia
pp. 291-291(1)
Authors: Brook S.; Walden J.; Mertens C.; Benattia I.

Cardiac conduction in females and males under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs
pp. 291-292(2)
Authors: Czekalla J.; Beasley C.; David S.; Berg P.H.; Stauffer V.; Boylan C.

Schizophrenia associated with extensive fronto-striatal lesions: A case treated by clozapine
pp. 292-292(1)
Authors: Fontana M.; Lega A.; Dario T.; Costantino D.; Di Fonzo T.; Hadjichristos A.

The schizophrenia clinical trial consortium for modeling placebo response
pp. 292-292(1)
Authors: Welge J.; Friedman L.; Keck P.E.

Switching to aripiprazole monotherapy
pp. 292-293(2)
Authors: Medori R.; Gharbia N.; Saha A.; Ali M.; Stock E.; Ingenito G.

Gender differences in schizophrenia: Results from the schizophrenia outpatient health outcomes study (SOHO)
pp. 293-293(1)
Authors: Haro J.M.; Gasquet I.; Lepine J.P.; Edgell E.T.; Frewer P.; Novick D.; Usall J.

Ziprasidone vs olanzapine for cognitive function in schizophrenia
pp. 293-293(1)
Authors: Harvey P.; Simpson G.M.; Loebel A.

Aripiprazole is a potent, partial agonist at cloned human D2L and native rat 5-HT1A receptors
pp. 293-294(2)
Authors: Jordan S.; Chen R.; Johnson J.; Regardie K.; Tadori Y.; Kikuchi T.

Metabolic adverse events among schizophrenics exposed to antipsychotics in the general practice research database
pp. 294-294(1)
Authors: Buchanan R.; L'Italien G.; Koro C.

Safety and tolerability of IM ziprasidone: Review of clinical trial data
pp. 294-294(1)
Authors: Zimbroff D.L.; Brook S.; Benattia I.

Anomalous cerebral structural asymmetry in patients with schizophrenia demonstrated by voxel-based morphometry
pp. 295-295(1)
Authors: Kawasaki Y.; Suzuki M.; Nohara S.; Hagino H.; Takahashi T.; Nakamura K.; Kurachi M.

Biases in the spontaneous reporting of adverse reactions: The sertindole saga
pp. 295-295(1)
Authors: Moore N.D.; Hall G.; Mann R.; Sturkenboom M.; Toumi F.

SLV310, a molecule combining potent dopamine D₂ receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity
pp. 296-296(1)
Authors: Tuinstra T.; Herremans A.H.J.; Van der Heyden J.A.M.; McCreary A.C.; Hesselink M.B.; Kruse C.G.; Long S.K.

Correlations between clinical symptoms, neurocognitive alterations and structural brain abnormalities in men with schizophrenia
pp. 296-297(2)
Authors: Szendi I.; Kiss M.; Voros E.; Kovacs Z.A.; Szekeres G.; Cimmer C.; Keri S.; Galsi G.; Boda K.; Csernay L.; Janka Z.

Atypical antipsychotic drugs stimulate feeding and inhibit cocaine-induced hyperactivity in Lister-hooded rats
pp. 297-297(1)
Authors: Hartfield A.W.; Moore N.A.; Clifton P.G.

The cognitive effects of conventional and atypical antipsychotics in schizophrenia
pp. 297-297(1)
Authors: Haraszti L.; Somogyi D.

Antidepressant-like influence of olanzapine on membrane phospholipase D activity in rat brain
pp. 297-298(2)
Authors: Krzystanke M.; Trzeciak H.I.; Krupka-Matuszczyk I.; Krzystanek E.

Atypical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on syllabic and language-related dichotic listening scores
pp. 298-298(1)
Author: Loza B.

Post-pubertal emergence of schizophrenia-like abnormalities following prenatal immune activation in rats
pp. 298-299(2)
Authors: Zuckerman L.; Rehavi M.; Nachman R.; Weiner I.

Fos-like immunoreactivity in rat brain induced by cytokine administration
pp. 299-299(1)
Authors: Akihiro O.; Kokai M.

No association between 5-HT2A receptor promoter gene polymorphism, 1438A/G and homicide in schizophrenics
pp. 299-299(1)
Authors: Chee I.-S.; Lee S.-W.; Lee Y.-H.

Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study
pp. 300-300(1)
Authors: Poyurovsky W.; Epshtein S.; Fuchs C.; Schneidman M.; Weizman R.; Weizman A.

EuropQoL-5D (a generic health-related quality of life measure): Psychometric validation in a sample of schizophrenic patients
pp. 300-300(1)
Authors: Prieto L.; Sacristan J.A.; Hormaechea J.A.; Gomez J.-C.

Sertindole is well tolerated and superior to risperidone with respect to efficacy in patients with schizophrenia
pp. 300-301(2)
Authors: Azorin J.-M.; Toumi M.; Sloth-Nielsen M.

Prolactic serum levels after long term risperidone treatment
pp. 301-301(1)
Authors: De Smedt G.; Binder C.; Findling R.; Kusumakar V.

Ginkgo biloba extract (EGb 761) modifies catalepsy induced by haloperidol or nitric oxide synthase inhibitor in mice
pp. 301-302(2)
Authors: De Oliveira R.M.W.; Fontana L.; Del Bel E.A.

Efficacy of amisulpride vs risperidone in the long-term treatment of chronic schizophrenia: Results from a 12 month double-blind study
pp. 302-302(1)
Authors: Rein W.; Fleurot O.

Identification of peripheral genetic markers of schizophrenia with cDNA chips
pp. 302-302(1)
Authors: Szekeres G.; Zvara A.; Hackler L.; Janka Z.; Santha M.; Puskas L.

Effectiveness and safety of olanzapine versus conventional antipsychotics in the treatment of inpatient with acute schizophrenia: A multivariate analysis
pp. 303-303(1)
Authors: Ciudad A.; Bobes J.; Alvarez E.; Canas F.; Carrasco J.L.; Gascon J.; Gibert J.; Gomez J.-C.; Gutierrez M.

Increased rates of antipsychotic-induced EPS in mood disorders: Myth or reality?
pp. 303-303(1)
Authors: Cavazzoni P.; Berg P.H.; Baker R.W.; Millikan M.; Evans A.R.; Wei H.; Tohen M.

Antipsychotic agents and serum creatine kinase levels
pp. 304-304(1)
Authors: Reznik I.; Spivak B.; Kotler M.; Weizman A.; Meltzer H.Y.; Mester R.

How to compare the safety and efficacy of antipsychotic therapies, with a lack of head to head trial evidence; the example of olanzapine versus quetiapine
pp. 304-304(1)
Authors: Croker V.; Montgomery W.; Mullen K.; Coleman K.; Davey P.

PET imaging of D1 and D2 receptors during treatment with novel antipsychotics
pp. 305-305(1)
Authors: Tauscher J.; Agid O.; Verhoeff N.P.L.G.; Harris P.; Zipursky R.B.; Kapur S.

Mental health services use among outpatients with schizophrenia in Egypt, Saudi Arabia, Turkey, and Algeria
pp. 305-306(2)
Authors: Nitz N.; Namjoshi M.; Dossenbach M.; Bitter I.; Janko C.; Becker S.; Richardson J.

Single daily dosing of quetiapine in first episode schizophrenia
pp. 306-306(1)
Authors: Tauscher-Wisniewski S.; Kapur S.; Tauscher J.; Jones C.; Daskalakis Z.J.; Zipursky R.B.

Mental health services use by outpatients with schizophrenia in Central and Eastern Europe
pp. 306-307(2)
Authors: Nitz N.; Namjoshi M.; Dossenbach M.; Bitter B.; Christa J.; Becker S.; Richardson J.

Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: An 18-month study
pp. 307-307(1)
Authors: Tohen M.; Suppes T.; Baker R.W.; Risser R.C.; Evans A.R.; Calabrese J.R.

Olanzapine versus haloperidol as initial treatment in acute mania: Prospective comparison of work functional outcomes
pp. 307-307(1)
Authors: Shi L.; Namjoshi M.; Juarez R.; Edgell E.T.; Tohen M.; Breier A.; Haro J.M.

Assessing the risk of antipsychotic-induced Type II diabetes among schizophrenics: A matched case-control study
pp. 307-308(2)
Authors: Lambert B.; Chou C.-H.; Chang K.-Y.; Iwamoto T.; Tafesse E.

Polymorphisms of SLC6A4, 5-HT2A and 5-HT6 genes and therapeutic resistance in schizophrenic inpatients
pp. 308-308(1)
Authors: Saltini A.; Bonvicini C.; Zanardini R.; Bignotti S.; Tura G.; Randazzo R.; Gennarelli M.

Olanzapine vs divalproex: Prospective comparison on self-reported cognitive function in patients with bipolar disorder
pp. 308-309(2)
Authors: Yurgelun-Todd D.; Shi L.; Zhu B.; Namjoshi M.; Tunis S.; Baker R.W.; Tohen M.

The critical role of serotonin receptor blockade in the action of clozapine and related atypical antipsychotic drugs
pp. 309-309(1)
Authors: Meltzer H.Y.; Li A.; Chung Y.; Ichikawa J.

Effect of conventional and atypical antipsychotics on neurogenesis in rats
pp. 309-309(1)
Authors: Mahadik S.; Chiu A.F.C.; Wakade C.

Safety of amisulpride vs risperidone in the long-term treatment of chronic schizophrenia: Results from a 12 month double-blind study
pp. 309-310(2)
Authors: Rein W.; Fleurot O.

Amisulpride: Metabolic and pharmacokinetic profile after 14C intravenous administration
pp. 310-310(1)
Authors: Canal M.; Espie P.; Thenot J.P.

Antipsychotics and quality of life among stable schizophrenia patients
pp. 310-310(1)
Authors: Arnould B.; Ingham M.; Lehman A.F.; Grogg A.; Duchesne I.

Ziprasidone vs olanzapine in schizophrenia: 6-Month continuation study
pp. 311-311(1)
Authors: Simpson G.M.; Weiden P.; Pigott T.; Romano S.J.; Siu C.

Incidence of first-episode psychosis in teenagers in Melbourne, Australia, 1997-2000
pp. 311-311(1)
Authors: Amminger G.P.; McGorry P.

Bone mineral density in premenopausal women with antipsychotic-induced hyperprolactinaemia
pp. 311-312(2)
Authors: Akande B.; Wieck A.; Haddad P.M.

Safety, efficacy and quality of life of olanzapine in first-episode schizophrenia - Results of the EFESO study
pp. 312-312(1)
Authors: Ciudad A.; Montes J.M.; Gascon J.; Gomez J.-C.

Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients
pp. 312-313(2)
Authors: Poyurovsky M.; Isaaks I.; Pashnian A.; Fuchs C.; Schneidman M.; Faragian S.; Weizman R.; Weizman A.

Oral risperidone in the management of agitated behavior in emergency settings
pp. 313-313(1)
Authors: Veser F.; Zealburg J.; Veser B.; Zhu Y.; Gharabawi G.

Ziprasidone vs amisulpride for negative symptoms of schizophrenia
pp. 313-313(1)
Authors: Olie J.-P.; Spina E.; Benattia I.

Serial measurement of sexual function using the DGSFi in an olanzapine switch trial
pp. 313-314(2)
Authors: Dickson R.A.; Violato C.; Smekal T.; Glazer W.M.; Remington G.J.; Stip E.; Walker D.J.; Jones B.

Ziprasidone vs risperidone in schizophrenia: An 8-week, double-blind trial
pp. 314-314(1)
Authors: Addington D.; Pantelis C.; Benattia I.

Statistical models for population heterogeneity in epidemiological longitudinal studies: Person centred latent class analysis to identify casemix groups in the schizophrenia outpatient health outcomes study
pp. 314-314(1)
Authors: Edgell E.T.; Croudace T.J.; Jones P.B.; Haro J.M.

Anticholinergic effect of atypical antipsychotics in elderly patients
pp. 315-315(1)
Authors: Tune L.; Mulsant B.; Gharabawi G.

Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial
pp. 315-315(1)
Authors: Namjoshi M.; Young C.; Huang L.; Edgell E.T.; Breier A.

An economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol
pp. 315-316(2)
Authors: Russell J.M.; Mackell J.A.

Effect of smoking status on olanzapine-induced weight gain
pp. 316-316(1)
Authors: Lasser R.; Gharabawi G.

Improvement of insulin indices after switch from olanzapine to risperidone
pp. 316-316(1)
Authors: Berry S.; Mahmoud R.

Sexual dysfunction and adherence to antipsychotic therapy in schizophrenia
pp. 316-317(2)
Authors: Weiden P.; Mackell J.A.; McDonell D.

Psychiatric care and profile of schizophrenic outpatients treated by psychiatrists in France. French baseline results from the 3-years, pan-European, observational SOHO (Schizophrenia Outpatient Health Outcomes) study
pp. 317-317(1)
Authors: Rost N.; Gasquet I.; Lepine J.P.

The treatment of schizophrenia across Europe: Between country baseline differences in the schizophrenia outpatient health outcomes (SOHO) study
pp. 317-317(1)
Authors: Edgell E.T.; Haro J.M.; Frewer P.; Wright P.; Novick D.

Sexual dysfunction during treatment of schizophrenia: A largely underestimated problem? Baseline results from the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study
pp. 317-318(2)
Authors: Dossenbach M.; Brunner E.; Levitt L.; Becker S.; Sammut K.; Madrigal L.; Roque A.

Patient characteristics and clinical status of patients prescribed monotherapy or combination antipsychotic treatment: Baseline results from the intercontinental outpatient health outcomes study (IC SOHO)
pp. 318-318(1)
Authors: Levitt L.; Becker S.; Dossenbach M.; Busselen M.; Png C.H.; Lee M.H.; Kim C.Y.

Amisulpride: Metabolic and pharmacokinetic profile after 14C oral administration
pp. 319-319(1)
Authors: Canal M.; Fraisse J.; Thenot J.P.

SLV310, a molecule combining potent dopamine D₂ receptor antagonism with serotonin reuptake inhibition: in vitro and in vivo neurochemistry
pp. 319-319(1)
Authors: Hesselink M.B.; Van Vliet B.; Kruse C.G.; Long S.K.

Neurocognitive effects of risperidone and haloperidol on first-episode schizophrenics
pp. 320-320(1)
Authors: Kabanov S.; Mosolov S.

A stratified dose comparison of risperidone and haloperidol: Impact on relapse prevention
pp. 320-320(1)
Authors: Vangeneugden T.; Augustyns I.; Curinckx H.; Ingham M.

Rivastigmine for the treatment of cognitive impairment in residual schizophrenia: A 6-month follow-up
pp. 321-321(1)
Authors: Lenzi A.; Maltinti E.; Tiano L.; Manca E.; Spagna F.; Coli E.

Donepezil for the treatment of cognitive impairment in residual schizophrenia: A 12-month follow-up
pp. 321-321(1)
Authors: Lenzi A.; Maltini E.; Poggi E.; Nassimbeni A.; Del Poggetto M.C.; Coli E.

''Normalization'' of disturbed sensory input circuits in neuroleptic-naive first-episode schizophrenic patients after treatment with atypical antipsychotics: A fMRI study
pp. 321-322(2)
Authors: Braus D.F.; Weber-Fahr W.; Ruf M.; Tost H.; Weimer E.; Brassen S.; Schmitt A.

The characteristics, treatment response, safety, and concominant medication use of patients receiving clozapine treatment
pp. 322-322(1)
Authors: Anil A.E.; Turgut I.T.; Kabakci E.; Rezaki M.; Gogus A.

Cognitive dysfunction in recent onset schizophrenia: Performance of unmedicated compared to medicated patients and healthy controls: A cross-sectional study
pp. 322-323(2)
Authors: Daban C.; Amado-Boccara I.; Willard D.; Krebs M.O.; Poirier M.F.

The efficacy and safety of olanzapine in combination with valproate or lithium in the treatment of mania
pp. 323-323(1)
Authors: Cetin M.; Basoglu C.; Ebrinc S.; Balibey H.; Baykiz A.F.; Maden B.

Prolactin and Risperidone in the current clinical practice: Results
pp. 323-323(1)
Author: Fricchione Parise V.

Antipsychotic profile of the novel benzopyranopyrrole and preferential dopamine D₃ receptor antagonist, S33138
pp. 324-324(1)
Authors: Millan M.J.; Dekeyne A.; Chamorro S.; Longchamp M.; Levens N.; Cussac D.; Newman-Tancredi A.; Silverdale M.; Brotchie J.; Dubuffet T.; Lavielle G.; Brocco M.

Antipsychotic drugs: A comparative study of acute effects on spontaneous locomotor activity and behavioural patterns in rats
pp. 324-324(1)
Authors: Antoniou K.; Papathanasiou G.; Nomikos G.; Hyphantis T.; Papadopoulou-Daifoti Z.

The effects of antipsychotic drugs on dopaminergic and serotonergic activity in the rat hypothalamus
pp. 325-325(1)
Authors: Daskas S.; Antoniou K.; Drossopoulou G.; Rimikis M.; Papadopoulou-Daifoti Z.

Primary negative symptoms in schizophrenia: Treatment with paroxetine in a double-blind placebo-controlled trial
pp. 325-325(1)
Authors: Jockers-Scherubl M.C.; Godemann F.; Bauer A.; Wolfensteller U.

Long-acting injectable risperidone: Efficacy and safety
pp. 325-325(1)
Authors: Kane J.M.; Eerdekens M.; Keith S.J.; Lesem M.; Karcher K.; Lindenmayer J.-P.

Repeated administration of olanzapine differentially affects slow wave sleep, sleep continuity and daytime sedation: A placebo controlled study of morning versus evening dosing in healthy volunteers
pp. 326-326(1)
Authors: Staner L.; Granier L.A.; Vandenhende F.; Macher J.-P.; Luthringer R.

Comparison of the effects on sleep EEG of morning versus evening administration of olanzapine: A placebo controlled study in healthy volunteers
pp. 326-326(1)
Authors: Staner L.; Haba J.; Granier L.A.; Vandenhende F.; Macher J.-P.; Luthringer R.

Evaluation of neonatal lesions of the ventral hippocampus as an animal model of schizophrenia
pp. 326-327(2)
Authors: Nayak S.; Ashton D.

Baseline results of patients initiating treatment with olanzapine or risperidone in the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study
pp. 327-327(1)
Authors: Levitt L.; Becker S.; Boland J.; Rodriguez I.; Dossenbach M.; Schawoush M.; Granim M.

Acute and chronic drug-induced akathisia: A clinical comparison
pp. 327-328(2)
Authors: Kim J.-H.; Kang U.G.; Yoon S.-C.; Kim Y.S.

Olanzapine vs risperidone: Impact on weight gain and blood lipids. Is there any relationship with antipsychotic efficacy?
pp. 328-328(1)
Authors: Dimelis D.; Garyfallos G.; Kiouniakis F.; Sidiropoulos N.; Lavrendiadis G.; Giouzepas I.; Fokas K.

Risperidone treatment of patients with chronic schizophrenia in a primary care setting
pp. 328-328(1)
Author: Nimatoudis I.

Atypical antipsychotics and cognitive brain activation in schizophrenia
pp. 328-328(1)
Authors: Quintana J.; Wong T.; Ortiz-Portillo E.; Marder S.; Mazziotta J.C.

Quetiapine in the treatment of borderline personality disorder
pp. 329-329(1)
Authors: Hilger E.; Barnas C.; Kasper S.

Therapeutic drug-monitoring of Amisulpride in schizophrenic patients
pp. 329-329(1)
Authors: Bergemann N.; Frick A.; Kopitz J.

A six-month, double-blind, controlled trial in schizophrenic patients comparing amisulpride and olanzapine. Preliminary results on short-term analysis
pp. 329-330(2)
Authors: Martins S.; Loo H.; Peuskens J.; Rein W.; Fleurot O.

Side effects and efficacy with combined therapy of clozapine and haloperidol in the treatment-resistant schizophrenic patients
pp. 330-330(1)
Authors: Jakovcevska-Kujundziska M.; Filovska V.; Lazarova V.; Serafimova T.

Automatic recognition of cerebral sulci in schizophrenia using a congregation of neural networks
pp. 330-331(2)
Authors: Bartres-Faz D.; Riviere D.; Le Provost J.B.; Artiges E.; Mangin J.F.; Paillere M.L.; Leboyer M.; Gallarda T.; Recasens C.; Martinot J.L.

Comparison of high-potency benzodiazepines vs. combination of high-potency benzodiazepines and fluoxetine in treatment of panic disorder with agoraphobia
pp. 331-331(1)
Authors: Latas M.; Starcevic V.

Shyness and the serotonin transporter promoter
pp. 331-332(2)
Authors: Arbelle S.; Benjamin J.; Golin M.; Kremer I.; Belmaker R.H.; Ebstein R.P.

Aversive role of nitric oxide in the inferior colliculus and in the dorsolateral periaqueductal gray
pp. 332-332(1)
Authors: Guimaraes F.S.; Moreira F.; Molchanov M.L.

Effects of DHEA-S on communicative and anxiety-like behavior in male mice following chronic exposure to social stress
pp. 332-333(2)
Authors: Amikishieva A.; Ovsyukova M.; Obut T.

''Compulsive'' lever pressing after post-training signal attenuation - A novel rat model of obsessive compulsive disorder: Preliminary pharmacology
pp. 333-333(1)
Authors: Joel D.; Doljansky J.

Anxiogenic-like activity of L-655,708, a selective ligand for the benzodiazepine site of GABAA receptors which contain the alpha-5 subunit, in the elevated-plus maze test
pp. 333-334(2)
Authors: Garcia F.; Buron E.; Martin M.; Navarro J.F.

CRF mediates conditioned anxiety to nicotine
pp. 334-334(1)
Authors: Tucci S.; Cheeta S.; Seth P.; File S.E.

Food deprivation potentiates anxiolytic effects of a low dose of nicotine in deprived female rats
pp. 334-334(1)
Authors: Genn R.F.; Tucci S.; Edwards J.; Thomas A.; File S.E.

Mirtazapine in posttraumatic stress disorder: Results of a placebo-controlled trial
pp. 334-335(2)
Authors: Connor K.M.; Davidson J.R.T.; Weisler R.H.; Butterfield M.I.; Casat C.D.

A controlled trial of combined sertraline and prolonged exposure therapy in posttraumatic stress disorder
pp. 335-335(1)
Authors: Connor K.M.; Rothbaum B.; Foa E.B.; Davidson J.R.T.; Cahill S.; Clary C.

Efficacy and safety of sertraline in obsessive compulsive disorder (OCD); 12 Weeks results of controlled clinical trial versus doxepin
pp. 335-336(2)
Author: Dan I.-A.

5-HT2A T102C gene polymorphism in Turkish patients with obsessive-compulsive disorder
pp. 336-336(1)
Authors: Tot S.; Erdal M.E.; Yazici K.; Herken H.; Yazici A.; Buturak V.

Serotonin transporter gene polymorphism in Turkish patients with obsessive compulsive disorder
pp. 336-336(1)
Authors: Tot S.; Erdal M.E.; Yazici K.; Herken H.; Yazici A.; Bal N.

-1438 G/A polymorphism of the 5HT2A receptor gene in Turkish patients with obsessive compulsive disorder
pp. 336-336(1)
Authors: Tot S.; Erdal M.E.; Yazici A.; Yazici K.; Metin O.

Characteristics of acute stress symptoms and lower nitric oxide concentration in young disaster workers in Taiwan
pp. 336-337(2)
Authors: Yeh C.-B.; Leckman J.; Wan F.-J.; Shiah I.-S.; Lu R.-B.

Characteristics of benzodiazepine users in a high-security Greek prison
pp. 337-337(1)
Authors: Lekka N.P.; Papadourakis A.; Beratis S.

Prevalence and impact of generalized anxiety and major depression in a Belgian primary care setting
pp. 337-338(2)
Authors: Fischler B.; Ansseau M.; Dierick M.; Mignon A.; Leyman S.

Behavioural response of gerbils to anxiolytics and antidepressants in the light and dark test
pp. 338-338(1)
Authors: Lapiz M.D.S.; Hogg S.

Anxiolytic effect concomitant to analgesic action of tramadol and gabapentin injected simultaneously to rat
pp. 338-339(2)
Authors: Panocka I.; Antkowiak B.; Kowalczyk M.

Right dorsolateral prefrontal rTMS in posttraumatic stress disorder: A double blind, placebo-controlled study
pp. 339-339(1)
Authors: Kouperman I.; Grisaru N.; Regina M.; Kaplan Z.; Cohen H.

The influence of neuropeptide Y on anxiolytic action of MPEP in the rat brain amygdala
pp. 339-339(1)
Authors: Wieronska J.M.; Szewczyk B.; Branski P.; Palucha A.; Obuchowicz E.; Smialowska M.

Citalopram challenge in social anxiety disorder
pp. 339-340(2)
Authors: Shlik J.; Maron E.; Aluoja A.; Vasar V.; Toru I.

Serotonin influences respiratory variability in freely moving rats: Implications for panic disorder
pp. 340-340(1)
Authors: Annerbrink K.; Olsson M.; Hedner J.; Eriksson E.

Panic disorder severity scale: Reliability and validity of the Turkish version
pp. 340-341(2)
Authors: Monkul S.; Fidaner H.; Tural U.; Tuncel E.; Alkin T.

Valproate in the treatment of posttraumatic stress disorder: An open-label study
pp. 341-341(1)
Authors: Otte C.; Yassouridis A.; Wiedemann K.; Kellner M.

Miscellaneous
pp. 341-341(1)
Authors: Arias F.; Soto J.A.; Garcia M.J.; Rodriguez-Calvin J.L.; Morales J.; Salgado M.

A placebo-controlled study of pregabalin and venlafaxine treatment of GAD
pp. 341-342(2)
Authors: Kasper S.; Blagden M.; Seghers S.; Veerman A.; Volz H.P.; Geniaux A.; Strub N.; Marchand A.; Maisonobe P.; Mikkelsen H.

St. John's wort extract (Ll 160) in somatoform disorders - Results of a placebo-controlled trial
pp. 342-342(1)
Authors: Murck H.; Moller H.J.; Volz H.P.